AB 1088: Public health: kratom.
- Session Year: 2025-2026
- House: Assembly
- Latest Version Date: 2026-06-08
Current Status:
In Progress
(2026-06-17: In committee: Set, first hearing. Hearing canceled at the request of author.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law, the Sherman Food, Drug, and Cosmetic Law, provides for the regulation of various subjects relating to the manufacturing, processing, labeling, advertising, and sale of food, drugs, and cosmetics, under the administration and enforcement of the State Department of Public Health (department) and in accordance with the Federal Food, Drug, and Cosmetic Act. The act generally requires manufacturers, packers, and holders of processed foods to register with the department. A violation of the act is a crime.
This bill would add kratom products and products containing 7-hydroxymitragynine (7-OH products), products, as defined, to the Sherman Food, Drug, and Cosmetic Law. The bill would prescribe specified quantities of alkaloids present in kratom products and 7-OH products and require a processor, as defined, to register with the department and to annually register each kratom product it manufactures, packages, distributes, or labels, which would include certification by a laboratory specifying that the product meets certain qualifications. The bill would establish labeling and packaging requirements for those products. The bill would prohibit the sale of kratom products and 7-OH products to those under 21 years of age. The bill would require the packaging of kratom products and 7-OH products to be child resistant and would prohibit the sale and manufacture of a kratom product or 7-OH product that is attractive to children. to those under 21 years of age and would prohibit the sale or distribution of those products at a premise or on an internet website or application that permits a person under 21 years of age to enter and remain or to complete the purchase of any product. The bill would prohibit the sale or distribution of a kratom product that has a child-attractive flavor, as defined. The bill would authorize the department to deny, suspend, or revoke a registration for actions taken in violation of these provisions. By expanding the scope of a crime, the bill would create a state-mandated local program.
This bill would require a purchaser of a kratom product to pay a tax on the purchase for use in this state of a kratom product from a retailer of 15% of the sales price from the sale of a kratom product. The bill would require a retailer to collect the tax from the purchaser at the time of the retail sale. The bill would require all revenues, interest, and penalties, less refunds, collected from the tax described above to be deposited into the Kratom Products Public Health and Safety Fund, a continuously appropriated fund created by the bill, and would require all amounts in the fund to be distributed to the University of California Kern County Medical Education Endowment Fund, the Board of State and Community Corrections, the Primary Care Account, and the Specialty Care Account, among others. By creating a continuously appropriated fund and allocating additional moneys to continuously appropriated funds, the bill would make an appropriation.
The bill would provide for the administration and collection of this tax pursuant to procedures set forth in the Fee Collection Procedures Law. By expanding the application of the Fee Collection Procedures Law, the violation of which is a crime, this bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Sherman Food, Drug, and Cosmetic Law, provides for the regulation of various subjects relating to the manufacturing, processing, labeling, advertising, and sale of food, drugs, and cosmetics, under the administration and enforcement of the State Department of Public Health (department) and in accordance with the Federal Food, Drug, and Cosmetic Act. The act generally requires manufacturers, packers, and holders of processed foods to register with the department. A violation of the act is a crime.
This bill would add kratom products and products containing 7-hydroxymitragynine (7-OH products), as defined, to the Sherman Food, Drug, and Cosmetic Law. The bill would prescribe specified quantities of alkaloids present in kratom products and 7-OH products and would establish labeling and packaging requirements for those products. The bill would prohibit the sale of kratom products and 7-OH products to those under 21 years of age. The bill would require the packaging of kratom products and 7-OH products to be child resistant and would prohibit the sale and manufacture of a kratom product or 7-OH product that is attractive to children. By expanding the scope of a crime, the bill would create a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Sherman Food, Drug, and Cosmetic Law, provides for the regulation of various subjects relating to the manufacturing, processing, labeling, advertising, and sale of food, drugs, and cosmetics, under the administration and enforcement of the State Department of Public Health (department) and in accordance with the Federal Food, Drug, and Cosmetic Act. The act generally requires manufacturers, packers, and holders of processed foods to register with the department. A violation of the act is a crime.
This bill would add kratom products and products containing 7-hydroxymitragynine (7-OH products), as defined, to the Sherman Food, Drug, and Cosmetic Law. The bill would prescribe specified quantities of alkaloids present in kratom products and 7-OH products and would establish labeling and packaging requirements for those products. The bill would prohibit the sale of kratom products and 7-OH products to those under 21 years of age. The bill would require the packaging of kratom products and 7-OH products to be child resistant and would prohibit the sale and manufacture of a kratom product or 7-OH product that is attractive to children. By expanding the scope of a crime, the bill would create a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law regulates the sale of various products in the State of California to protect the health and safety of California consumers, including drug masking products and toxic substances.This bill would prohibit the sale, offer for sale, provision, or distribution of kratom leaf, a kratom product, or any product containing 7-Hydroxymitragynine to a person under 21 years of age.Existing law regulates the sale of various products in the State of California to protect the health and safety of California consumers, including drug masking products and toxic substances.
This bill would prohibit the sale, offer for sale, provision, or distribution of kratom leaf, a kratom product, or any product containing 7-Hydroxymitragynine to a person under 21 years of age.
As used in this article, the following terms have the following definitions:
(a)7-OH product means a product containing 7-hydroxymitragynine. (b)(a)Attractive to children means any of the following:
(1)Use of images that are attractive to children, including, but not limited to, images of any of the following, except as part of required health warnings:
(A)Cartoons, toys, or robots.
(B)Any real or fictional humans.
(C)Fictional animals or creatures.
(D)Fruits or vegetables, except when used to accurately describe ingredients or flavors contained in a product. vegetables.
(2)Likeness to images, characters, or phrases that are popularly used to advertise to children.
(3)Imitation of candy packaging or labeling, or other packaging and or labeling of cereals, sweets, chips, or other food products typically marketed to children.
(4)The terms candy or candies or variants in spelling such as kandy or kandee.
(5)Brand names or close imitations of brand names of candies, cereals, sweets, chips, or other food products typically marketed to children.
(6)Any other image or packaging that is easily confused with commercially available foods that do not contain kratom and are typically marketed to children.
(7)Anything else that the department determines in regulation to be attractive to children.
(8)Anything else that is attractive to children in light of all relevant facts and circumstances.
(b)Characterizing flavor means a taste or odor, distinguishable by an ordinary consumer either prior to or during the consumption of a kratom product, other than the taste or odor of kratom leaf or kratom leaf extract, including, but not limited to, tastes or odors relating to any fruit, chocolate, vanilla, honey, candy, cocoa, dessert, alcoholic beverage, menthol, mint, wintergreen, herb, or spice, or a cooling sensation distinguishable by an ordinary consumer during the consumption of a kratom product.
(c)Child-attractive flavor means a characterizing flavor, that is often used for the purpose of appealing to persons under 21 years of age.
(d)Kratom alkaloid means all of the following:
(1)7-hydroxymitragynine.
(2)Mitragynine.
(3)Paynantheine.
(4)Speciociliatine.
(5)Speciogynine.
(6)Any chemically converted, synthesized, modified, or novel derivatives of these alkaloids.
(c)(e)Kratom leaf means the leaf of the kratom plant, also known as mitragyna speciosa, in any form.
(d)(f)Kratom leaf extract means the material obtained by extraction of kratom leaves by any means.
(e)(g)Kratom product means a product consisting of kratom leaf, kratom leaf extract, or both. any kratom alkaloid regardless of whether it was derived from kratom leaf or kratom leaf extract.
(f)Total kratom alkaloids means the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-hydroxymitragynine in a kratom product.(h)Processor means the party responsible for manufacturing, packaging, labeling, or distributing a kratom product, or the party that advertises, represents, or holds itself out as manufacturing, preparing, packaging, or labeling a kratom product.
111224.83.Packaging of a kratom product or a 7-OH product offered for retail sale shall be child resistant for the life of the product. Both of the following packages are considered child resistant for the purposes of this section:(a)A package that has been certified as child resistant under the requirements of the Poison Prevention Packaging Act of 1970 (15 U.S.C. Sec. 1471 et seq.) and any regulations promulgated pursuant to that act.(b)Plastic packaging that is at least four mils thick and heat sealed without an easy-open tab, dimple, corner, or flap, provided that the package maintains its child resistance throughout the life of the product.111224.83.Packaging of a kratom product offered for retail sale shall meet the poison prevention packing standards under Part 1700 of Title 16 of the Code of Federal Regulations, as it read on January 1, 2027.
111224.84.(a)A kratom product produced, manufactured, distributed, sold, or offered for sale shall have a label that clearly and conspicuously provides all of the following information on each retail package:
(1)The following statement: WARNING: It is illegal to sell kratom to any person under 21 years of age. Kratom is not approved as a medication or to assist in the treatment of opioid addiction. Kratom is not approved as a harm reduction product. Kratom may be habit forming.
(2)The name and place of business of the processor.
(3)Quantitative declarations of each kratom alkaloid within the package.
(b)An individual, business, or other entity shall not make any health claims with regard to the use of a kratom product. This prohibition applies to health claims made explicitly or implicitly, including, but not limited to, labeling, packaging, advertising, marketing, branding, or naming of any kratom leaf or kratom product. For purposes of this section, health claims include labeling, packaging, advertising, marketing, branding, or naming any kratom product in a manner that resembles or references a drug product, a food, or a food additive.
111224.85.(a)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product or 7-OH product to a person under 21 years of age.
(b)An online retailer or marketplace of a kratom product or 7-OH product shall implement an age-verification system to ensure compliance with subdivision (a). (c)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product or 7-OH product that is attractive to children.(d)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product or 7-OH product with a level of 7-hydroxymitragynine that is greater than 2 percent of the total kratom alkaloids in the product.(b)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product at a premise or on an internet website or application that permits a person under 21 years of age to enter and remain or permits a person under 21 years of age to complete a purchase of any product.
(c)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product with a child-attractive flavor.
(d)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product that exceeds either of the following limits:
(1)Seventy-five milligrams of mitragynine per package.
(2)Fifty-seven hundredths of one milligram of 7-hydroxymitragynine per package.
(e)This article does not authorize the sale of any kratom product that is otherwise prohibited by state or federal law.
111224.87.(a)A processor shall register pursuant to Section 111224.89 and shall annually register each kratom product it manufactures, packs, distributes, or labels. A product that contains the same ingredients in the same delivery form but in a different container, package, or volume shall be included under the processors individual registration.
(b)Annual registration of a kratom product shall include a certificate of analysis from an independent laboratory. The laboratory shall be accredited under the standards of the International Organization for Standardization 17025:2017 accreditation from an accreditation body that is a signatory to the International Laboratory Accreditation Cooperation Mutual Recognition Arrangement.
(c)The certificate of analysis shall confirm the contents of the kratom product and include a certification that the product complies with all of the requirements for a kratom product in this article.
(d)The department may require an independent third-party test of a registered kratom product by a laboratory of the departments choice, and the processor shall be required to submit payment for the test and an equitable administrative fee within a reasonable time. If the processor does not tender payment to the department within 30 days of receipt of the invoice for the testing and administrative fee, the department shall revoke the registration for that product.
111224.89.(a)The department, in implementing this article, may establish an annual fee or assessment for any processor registering to produce, manufacture, or offer for sale a kratom product.
(b)The department may develop registration fees based on the number of units produced by registrants and total annual sales in California. The fee schedule may consist of tiers of registration fees denoted by unit production, total annual sales in California, and corresponding fees to the number of units produced and annual sales in California. The fees shall not exceed the reasonable regulatory costs of administering this article. The calculation of estimated fees is exempt from the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code).
(c)A processor shall operate in conformance with this article and in good faith compliance with their responsibilities under this article.
(d)A violation of this article shall be grounds for denying, suspending, forfeiting, revoking, or surrendering a registration. The department may deny, suspend, forfeit, revoke, or order to surrender a registration issued under this article.
(e)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department shall have the authority to promulgate regulations as may be necessary to implement this article.
(f)The department may execute an interagency agreement with other state or local government agencies in the performance of any or all of the requirements of this section.
111224.9.(a)For purposes of this section, the following definitions apply:
(1)Purchase has the same meaning as defined in Section 6010 of the Revenue and Taxation Code.
(2)Purchaser means a person who purchases a kratom product.
(3)Retail sale has the same meaning as defined in Section 6007 of the Revenue and Taxation Code.
(4)Retailer has the same meaning as defined in Section 6015 of the Revenue and Taxation Code.
(5)Sales price has the same meaning as defined in Section 6011 of the Revenue and Taxation Code.
(6)Use has the same meaning as defined in Section 6009 of the Revenue and Taxation Code.
(b)(1)(A)Beginning July 1, 2027, a purchaser shall pay a tax on the purchase for use in this state of a kratom product at a rate of 15 percent of the sales price of the kratom product.
(B)There is a rebuttable presumption that a kratom product is purchased for use in this state if either of the following is true:
(i)The kratom product is purchased from a retailer physically located in this state.
(ii)The address to which the retailer ships the purchased kratom product is located in this state.
(2)A retailer shall collect the tax imposed by this section from the purchaser at the time of the retail sale of a kratom product.
(c)(1)The department shall collect the tax imposed by this section pursuant to the Fee Collection Procedures Law (Part 30 (commencing with Section 55001) of Division 2 of the Revenue and Taxation Code).
(2)For purposes of this section, the references in the Fee Collection Procedures Law to fee shall include the tax imposed by this section, and references to feepayer shall include any retailer liable for the payment, pursuant to subdivision (c), of the tax imposed by this article.
(3)A retailer may retain 1 percent of the tax imposed by this section as reimbursement for all costs associated with collection of the tax and shall transmit the remainder of the tax to the department pursuant to subdivision (c).
(d)(1)Except as provided in paragraph (3), the tax imposed by this section shall be due and payable quarterly on or before the last day of the month following each calendar quarter.
(2)(A)The payments shall be accompanied by a return filed by the retailer using electronic media on or before the last day of the month following each quarterly period for the preceding quarterly period.
(B)Returns shall be authenticated in a form or pursuant to methods as may be prescribed by the department.
(3)The department may require the payment of the tax imposed by this section and the filing of returns for other than quarterly periods.
(e)The tax that is required to be collected by the retailer and any amount unreturned to the purchaser that is not tax but was collected from the purchaser under the representation by the retailer that it was tax constitutes debts owed by the retailer to the state.
(f)A retailer subject to the provisions of this section shall register for a permit with the department using electronic media and shall set forth the name under which it transacts or intends to transact business and any other information as the department may require.
(g)(1)The department may prescribe, adopt, and enforce regulations relating to the administration and enforcement of this section, including, but not limited to, collections, reporting, refunds, and appeals.
(2)(A)The department may prescribe, adopt, and enforce emergency regulations as necessary to implement this article.
(B)An emergency regulation prescribed, adopted, or enforced pursuant to this paragraph shall be adopted in accordance with Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, and, for purposes of that chapter, including Section 11349.6 of the Government Code, the adoption of the regulation is an emergency and shall be considered by the Office of Administrative Law as necessary for the immediate preservation of the public peace, health and safety, and general welfare.
111224.92.(a)(1)The Kratom Products Public Health and Safety Fund is hereby established in the State Treasury.
(2)Notwithstanding Section 13340 of the Government Code, all moneys in the fund are continuously appropriated, without regard to fiscal year, for the purposes described in this section.
(b)All revenues, interest, and penalties derived from the taxes imposed by Section 111224.9 shall be deposited into the Kratom Products Public Health and Safety Fund.
(c)The Controller shall annually allocate and transfer the moneys in the Kratom Products Public Health and Safety Fund as follows:
(1)Twenty-five percent shall be transferred to the University of California Kern County Medical Education Endowment Fund established in Section 92168 of the Education Code.
(2)Twenty-five percent shall be transferred to the Board of State and Community Corrections to support grant programs for local law enforcement that support efforts to combat human trafficking, illicit drug trafficking, or reduce community-based violence.
(3)Twenty percent shall be transferred to the Primary Care Account described in Section 14199.109 of the Welfare and Institutions Code.
(4)Twenty percent shall be transferred to the Specialty Care Account described in Section 14199.110 of the Welfare and Institutions Code.
(5)Five percent shall be transferred to the State Department of Public Health for costs associated with regulating kratom products.
(6)Five percent shall be transferred to the California Department of Tax and Fee Administration for costs associated with administrating this article.
SEC. 2.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
As used in this article, the following terms have the following definitions:
(a)7-OH product means a product containing 7-hydroxymitragynine.
(b)Attractive to children means any of the following:
(1)Use of images that are attractive to children, including, but not limited to, images of any of the following, except as part of required health warnings:
(A)Cartoons, toys, or robots.
(B)Any real or fictional humans.
(C)Fictional animals or creatures.
(D)Fruits or vegetables, except when used to accurately describe ingredients or flavors contained in a product.
(2)Likeness to images, characters, or phrases that are popularly used to advertise to children.
(3)Imitation of candy packaging or labeling, or other packaging and labeling of cereals, sweets, chips, or other food products typically marketed to children.
(4)The terms candy or candies or variants in spelling such as kandy or kandee.
(5)Brand names or close imitations of brand names of candies, cereals, sweets, chips, or other food products typically marketed to children.
(6)Any other image or packaging that is easily confused with commercially available foods that do not contain kratom and are typically marketed to children.
(7)Anything else that the department determines in regulation to be attractive to children.
(8)Anything else that is attractive to children in light of all relevant facts and circumstances.
(c)Kratom leaf means the leaf of the kratom plant, also known as mitragyna speciosa, any form.
(d)Kratom leaf extract means the material obtained by extraction of kratom leaves by any means.
(e)Kratom product means a product consisting of kratom leaf, kratom leaf extract, or both.
(f)Total kratom alkaloids means the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-hydroxymitragynine in a kratom product.
111224.83.Packaging of a kratom product or a 7-OH product offered for retail sale shall be child resistant for the life of the product. Both of the following packages are considered child resistant for the purposes of this section:
(a)A package that has been certified as child resistant under the requirements of the Poison Prevention Packaging Act of 1970 (15 U.S.C. Sec. 1471 et seq.) and any regulations promulgated pursuant to that act.
(b)Plastic packaging that is at least four mils thick and heat sealed without an easy-open tab, dimple, corner, or flap, provided that the package maintains its child resistance throughout the life of the product.
111224.85.(a)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product or 7-OH product to a person under 21 years of age.
(b)An online retailer or marketplace of a kratom product or 7-OH product shall implement an age-verification system to ensure compliance with subdivision (a).
(c)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product or 7-OH product that is attractive to children.
(d)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product or 7-OH product with a level of 7-hydroxymitragynine that is greater than 2 percent of the total kratom alkaloids in the product.
111224.86.Notwithstanding Article 2 (commencing with Section 110460) or any other law, an individual, business, or other entity that produces, sells, offers for sale, or distributes a kratom product or a 7-OH product is not required to register with or seek licensure from the department.SEC. 2.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
As used in this article, the following terms have the following definitions:
(a)7-OH product means a product containing 7-hydroxymitragynine.
(b)Attractive to children means any of the following:
(1)Use of images that are attractive to children, including, but not limited to, images of any of the following, except as part of required health warnings:
(A)Cartoons, toys, or robots.
(B)Any real or fictional humans.
(C)Fictional animals or creatures.
(D)Fruits or vegetables, except when used to accurately describe ingredients or flavors contained in a product.
(2)Likeness to images, characters, or phrases that are popularly used to advertise to children.
(3)Imitation of candy packaging or labeling, or other packaging and labeling of cereals, sweets, chips, or other food products typically marketed to children.
(4)The terms candy or candies or variants in spelling such as kandy or kandee.
(5)Brand names or close imitations of brand names of candies, cereals, sweets, chips, or other food products typically marketed to children.
(6)Any other image or packaging that is easily confused with commercially available foods that do not contain kratom and are typically marketed to children.
(7)Anything else that the department determines in regulation to be attractive to children.
(8)Anything else that is attractive to children in light of all relevant facts and circumstances.
(c)Kratom leaf means the leaf of the kratom plant, also known as mitragyna speciosa, any form.
(d)Kratom leaf extract means the material obtained by extraction of kratom leaves by any means.
(e)Kratom product means a product consisting of kratom leaf, kratom leaf extract, or both.
(f)Total kratom alkaloids means the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-hydroxymitragynine in a kratom product.
111224.83.Packaging of a kratom product or a 7-OH product offered for retail sale shall be child resistant for the life of the product. Both of the following packages are considered child resistant for the purposes of this section:
(a)A package that has been certified as child resistant under the requirements of the Poison Prevention Packaging Act of 1970 (15 U.S.C. Sec. 1471 et seq.) and any regulations promulgated pursuant to that act.
(b)Plastic packaging that is at least four mils thick and heat sealed without an easy-open tab, dimple, corner, or flap, provided that the package maintains its child resistance throughout the life of the product.
111224.85.(a)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product or 7-OH product to a person under 21 years of age.
(b)An online retailer or marketplace of a kratom product or 7-OH product shall implement an age-verification system to ensure compliance with subdivision (a).
(c)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product or 7-OH product that is attractive to children.
(d)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute a kratom product or 7-OH product with a level of 7-hydroxymitragynine that is greater than 2 percent of the total kratom alkaloids in the product.
111224.86.Notwithstanding Article 2 (commencing with Section 110460) or any other law, an individual, business, or other entity that produces, sells, offers for sale, or distributes a kratom product or a 7-OH product is not required to register with or seek licensure from the department.
SEC. 2.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SECTION 1.Chapter 3 (commencing with Section 24378) is added to Division 20 of the Health and Safety Code, to read:3.Kratom Age Limitation24378.An individual, business, or other entity shall not sell, offer for sale, provide, or distribute kratom leaf, a kratom product, or any product containing 7-Hydroxymitragynine to a person under 21 years of age.An individual, business, or other entity shall not sell, offer for sale, provide, or distribute kratom leaf, a kratom product, or any product containing 7-Hydroxymitragynine to a person under 21 years of age.
|
Date
|
Status
|
|---|---|
| Jun 17, 2026 | In committee: Set, first hearing. Hearing canceled at the request of author. |
| Jun 10, 2026 | Re-referred to Coms. on HEALTH and REV. & TAX. |
| Jun 9, 2026 | Re-referred to Com. on RLS. |
| Jun 9, 2026 | Withdrawn from committee. |
| Jun 9, 2026 | In committee: Hearing postponed by committee. |
| Jun 8, 2026 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 11, 2025 | Referred to Com. on HEALTH. |
| Jun 3, 2025 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Jun 2, 2025 | Read third time. Passed. Ordered to the Senate. (Ayes 76. Noes 0. Page 1876.) |
| May 27, 2025 | Read second time. Ordered to third reading. |
| May 23, 2025 | From committee: Do pass. (Ayes 14. Noes 0.) (May 23). |
| May 21, 2025 | Joint Rule 62(a), file notice suspended. (Page 1627.) |
| May 21, 2025 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| May 14, 2025 | In committee: Hearing postponed by committee. |
| Apr 30, 2025 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 7. Noes 0.) (April 29). Re-referred to Com. on APPR. |
| Apr 23, 2025 | From committee: Do pass and re-refer to Com. on E.S & T.M. (Ayes 16. Noes 0.) (April 22). Re-referred to Com. on E.S & T.M. |
| Apr 22, 2025 | Re-referred to Com. on HEALTH. |
| Apr 21, 2025 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Apr 21, 2025 | Re-referred to Com. on HEALTH. |
| Apr 10, 2025 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Apr 3, 2025 | In committee: Hearing postponed by committee. |
| Mar 10, 2025 | Referred to Coms. on HEALTH and E.S & T.M. |
| Feb 21, 2025 | From printer. May be heard in committee March 23. |
| Feb 20, 2025 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jun 2, 2025 | AB 1088 Bains Assembly Third Reading | Assembly Floor |
Passed |
|
| May 23, 2025 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 29, 2025 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Environmental Safety and Toxic Materials |
Passed |
|
| Apr 22, 2025 | Do pass and be re-referred to the Committee on [Environmental Safety and Toxic Materials] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Arcadia Police Officers' Association | ** Support | |
| Brea Police Association | ** Support | |
| Burbank Police Officers' Association | ** Support | |
| California Association of School Police Chiefs | ** Support | |
| California Coalition of School Safety Professionals | ** Support | |
| California District Attorneys Association | ** Support | |
| California Narcotic Officers' Association | ** Support | |
| California Reserve Peace Officers Association | ** Support | |
| California Retail and Distribution Fairness Association | ** Against | |
| California Statewide Law Enforcement Association (unless amended) | ** Against | |
| Claremont Police Officers' Association | ** Support | |
| cleanearth4kids.org | ** Support | |
| Consumer Action for a Strong Economy | ** Against | |
| Consumer Choice Center | ** Against | |
| Corona Police Officers' Association | ** Support | |
| County of Santa Barbara | ** Support | |
| Culver City Police Officers' Association | ** Support | |
| End It For Good | ** Against | |
| Families for America | ** Against | |
| Fullerton Police Officers' Association | ** Support | |
| Hispanic Leadership Fund | ** Against | |
| Holistic Alternative Recovery Trust | ** Against | |
| Holistic Alternative Recovery Trust (unless amended) | ** Against | |
| Infused Partners | ** Against | |
| Kreleaf | ** Against | |
| League Of California Cities | ** Support | |
| Los Angeles School Police Management Association | ** Support | |
| los angeles school police officers association | ** Support | |
| Murrieta Police Officers' Association | ** Support | |
| Newport Beach Police Association | ** Support | |
| Palos Verdes Police Officers' Association | ** Support | |
| Placer County Deputy Sheriffs' Association | ** Support | |
| Pomona Police Officers' Association | ** Support | |
| Riverside Police Officers' Association | ** Support | |
| Riverside Sheriffs' Association | ** Support | |
| Santa Ana Police Officers Association | ** Support | |
| Students for Sensible Drug Policy | ** Against | |
| Taxpayers Protection Alliance | ** Against |
SENATE COMMITTEE ON HEALTH
Senator Akilah Weber Pierson, Chair
BILL NO: AB 1088
AUTHOR: | Bains | ||
VERSION: | June 8, 2026 | ||
HEARING DATE: | June 17, 2026 | ||
CONSULTANT: | Vincent D. Marchand and Natalie Gehred | ||
SUBJECT: Public health: kratom
SUMMARY:
Adds kratom products to the Sherman Food, Drug, and Cosmetic Law. Requires kratom processors to register themselves and their products annually with CDPH and requires laboratory certificates of analysis for all products. Places limits of 75mg mitragynine and 0.57mg of 7-hydroxymitragynine per package and establishes poison prevention packaging and labeling requirements. Prohibits the sale or distribution of kratom products to anyone under 21 years of age at a premise or internet website or application that permits anyone under 21 to enter and remain or complete a purchase of any product. Prohibits the sale or distribution of a kratom product that has a child-attractive flavor. Establishes a 15% retail tax on kratom products purchased for use in the state to fund the Kratom Products Public Health and Safety Fund.
Existing law:
- Enacts the Sherman Food, Drug and Cosmetic Law (Sherman Law), enforced by the California Department of Public Health (CDPH), which provides broad authority for CDPH to enforce food safety requirements, including that food is not adulterated, misbranded, or falsely advertised. Food labeling requirements generally adopt federal food labeling laws as the state requirement, but CDPH is permitted, by regulation, to adopt additional food labeling regulations. [HSC §109875, et seq.]
- Establishes penalties for violations of the Sherman Law, including a fine of up to $1,000, or up to $10,000 for repeated violations. [HSC §111825]
- Prohibits any manufacturer, wholesaler, retailer, or other person to sell, transfer, or otherwise furnish a dietary supplement containing either of the following to a person under 18 years of age:
- A dietary supplement containing an ephedrine group alkaloid; or,
- A dietary supplement containing any of the following: androstanediol, androstanedione, androstenedione, norandrostenediol, norandrostenedione, dehydroepiandrosterone. [HSC §110423.2]
- Establishes a regulatory structure in CDPH, under the Sherman Law, for food, beverage and cosmetic products containing industrial hemp, and limits these products to containing no more than 0.3% concentration of tetrahydrocannabinol (THC). Prohibits industrial hemp from including cannabinoids produced through chemical synthesis. [HSC §111920, et seq. and §111920(f)]
- Enacts the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) to establish a comprehensive system to control and regulate the cultivation, distribution, transport, storage, manufacturing, processing, and sale of both medicinal cannabis and cannabis products, and adult-use cannabis and cannabis products for adults 21 years of age and over, regulated by the Department of Cannabis Control (DCC). [BPC §26000, et seq.]
This bill:
- Defines the following terms:
- “Attractive to children” means uses of images attractive to children, including cartoons, toys, robots, real or fictional humans, fictional animals or creatures, and fruits and vegetables; likenesses to images, characters, or phrases that are popularly used to advertise to children; imitation of the packaging or labeling of food products typically marketed to children; the terms “candy” or “candies” or variants in spelling; brand names or imitations of brand names of food products typically marketed to children; packaging that is similar to products that do not contain kratom and are typically marketed to children; or anything else deemed attractive to children in light of all relevant facts and circumstances;
- “Characterizing flavor” means a taste or odor other than the taste or odor of kratom leaf or kratom leaf extract, including, but not limited to, tastes or odors relating to any fruit, chocolate, vanilla, honey, candy, cocoa, dessert, alcoholic beverage, menthol, mint, wintergreen, herb, or spice, or a cooling sensation distinguishable by an ordinary consumer during the consumption of a kratom product;
- “Child-attractive flavor” means a characterizing flavor, that is often used for the purpose of appealing to persons under 21 years of age;
- “Kratom alkaloid” means 7-hydroxymitragynine, mitragynine, paynantheine, speciociliatine, speciogynine, and any chemically converted, synthesized, modified, or novel derivatives of these alkaloids;
- “Kratom leaf” means the leaf of the kratom plant, also known as Mitragyna speciosa, in any form;
- “Kratom leaf extract” means the material obtained by extraction of kratom leaves by any means;
- “Kratom product” means a product consisting of kratom leaf, kratom leaf extract, or any kratom alkaloid regardless of whether it was derived from kratom leaf or kratom leaf extract; and,
- “Processor” means the party responsible for manufacturing, packaging, labeling, or distributing a kratom product, or the party that advertises, represents, or holds itself out as manufacturing, preparing, packaging, or labeling a kratom product.
- Requires the packaging of a kratom product offered for retail sale to meet the poison prevention packing standards under specified provisions of the federal Poison Prevention Packaging Act, as those regulations read on January 1, 2027.
- Requires a kratom product produced, manufactured, distributed, sold, or offered for sale in the state of California to have a label that clearly and conspicuously provides all of the following information on each retail package:
- “WARNING: It is illegal to sell kratom to any person under 21 years of age. Kratom is not approved as a medication or to assist in the treatment of opioid addiction. Kratom is not approved as a harm reduction product. Kratom may be habit forming.”;
- The name and place of business of the processor; and,
- Quantitative declarations of each kratom alkaloid within the package.
- Prohibits an individual, business, or other entity from making any health claims regarding the use of a kratom product, either implicitly or explicitly, including, but not limited to: labeling, packaging, advertising, marketing, branding, or naming, including in a manner that resembles or references a drug product, a food, or a food additive.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product at a premise or on an internet website or application that permits a person under 21 years of age to enter and remain or permits a person under 21 years of age to complete a purchase of any product.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product with a child-attractive flavor, as defined.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product that exceeds either of the following limits or is otherwise prohibited by state or federal law:
- 75 mg/package of mitragynine; or,
- 0.57mg/package of 7-hydroxymitragynine (7-OH)
- Requires a kratom processor to register with CDPH and annually register each kratom product it manufactures, packs, distributes, or labels. Annual registration of each kratom product must include a certificate of analysis from an independent laboratory, as specified, that shall confirm the contents of the kratom product and certify that the product complies with all requirements in this bill.
- Authorizes CDPH to require an independent third-party test of a registered kratom product and requires CDPH to revoke the registration of a product if the processor does not tender payment for the test and an equitable administrative fee within 30 days of receipt of the invoice.
- Authorizes CDPH to develop registration fees to implement this article based on the number of units produced by registrants and total annual sales in California. Requires that fees not exceed the reasonable regulatory costs of administration and exempts the calculation of estimated fees from the Administrative Procedure Act.
- Authorizes CDPH to promulgate regulations or execute an interagency agreement with other state or local government agencies to implement this article. Requires processors to operate in good faith compliance and specifies that violations of this article shall be grounds for denying, suspending, forfeiting, revoking, or surrendering a registration.
- Institutes a 15% retail sales tax on the purchase of a kratom product if the kratom product is purchased from a retailer located in the state or the address to which the retailer ships the purchased product is shipped is in the state. Authorizes the retailer to retain one percent of the tax as a reimbursement for costs associated with tax collection.
- Requires each retailer to register for a permit with the California Department of Tax and Fee Administration (CDTFA) and authorizes CDTFA to collect the tax. Authorizes CDTFA to prescribe, adopt, and enforce regulations relating to the implementation, administration, and enforcement of the tax.
- Establishes the Kratom Products Public Health and Safety Fund in the State Treasury for all revenues, interest, and penalties from the taxes in this bill. Continuously appropriates moneys in the fund to the following:
- 25% to the University of California Kern County Medical Education Endowment Fund;
- 25% to the Board of State and Community Corrections;
- 20% to the Primary Care Account;
- 20% to the Specialty Care Account;
- 5% to CDPH for costs associated with regulating kratom products; and,
- 5% to CDTFA for administering the tax.
FISCAL EFFECT:
The current version of this bill has not been analyzed by a fiscal committee.
PRIOR VOTES:
Assembly Floor: | 76 - 0 |
Assembly Appropriations Committee: | 14 - 0 |
Assembly Environmental Safety and Toxic Materials Committee: | 7 - 0 |
Assembly Health Committee: | 16 - 0 |
COMMENTS:
- Author’s statement. According to the author, as a physician and addiction specialist, she presents this bill to establish urgently needed, comprehensive regulations on kratom. While kratom is an unapproved, non-benign substance that she advises her patients against using, it currently operates in a dangerous regulatory gray zone where it is widely accessible to minors. Unscrupulous companies are utilizing the Big Tobacco playbook to hook a new generation, exploiting legal loopholes under the false guise of "harm reduction.” This bill will finally bring accountability to the kratom market by setting a strict legal age limit of 21, mandating child-resistant packaging, banning marketing tactics that appeal to kids, and prohibiting products that artificially increase natural chemical concentrations. California should not wait for another youth addiction crisis to unfold before acting.
- Kratom and its use. According to a November 2023 report by the Congressional Research Service (CRS), kratom is a tree related to the coffee plant and is native to parts of Southeast Asia. Peoples indigenous to the tree’s range have traditionally consumed the leaves of the tree for medicinal and other purposes. Some commentators have raised safety concerns over kratom use, while others have suggested various beneficial uses. At low doses, kratom is a mild stimulant, but higher doses elicit sedative and analgesic responses due to alkaloids in the plant that activate opioid receptors. Studies indicate that kratom can be habit-forming, and a study in Drug and Alcohol Dependence of regular kratom leaf tea drinkers described physical and psychological withdrawal symptoms in those who ceased use. The CRS report additionally highlights that some kratom products intended for sale in the U.S. have been found to contain dangerous contaminants, such as salmonella and heavy metals.
According to the National Institute on Drug Abuse (NIDA), much is still unknown about kratom alkaloids, the short- and long-term health and safety impacts of kratom use, and kratom’s potential therapeutic uses. NIDA supports and conducts research on kratom to help inform kratom policy and health decision-making around kratom use. While kratom or its related compounds have not been approved by the FDA as safe and effective for any medical use, people report using kratom products to alleviate drug withdrawal symptoms and cravings, particularly for opioids, to alleviate pain, and to help manage mental health problems.
According to NIDA, people typically use kratom by swallowing raw plant matter in capsule or powder form, by mixing kratom powder into food or drinks, brewing the leaves as a tea, or taking liquid kratom extract. The 2022 National Survey on Drug Use and Health by the Substance Abuse and Mental Health Services Administration found that 0.7% (1.9 million people) of those 12 or older surveyed used kratom. The percentage was highest among young adults aged 18 to 25 (1.1% or 371,000 people) followed by adults 26 or older, then by adolescents aged 12 to 17 (0.1% or 26,000 people). However, kratom use is rising in the U.S.; social media analyses from the National Drug Early Warning System identify increasing kratom and 7-OH product discussion, rising steadily from May 2024 to May 2025. - Mitragynine and 7-OH. Kratom leaves contain a blend of many biologically active alkaloids that contribute to psychoactivity, the best studied of which are mitragynine and 7-OH. Mitragynine, the dominant alkaloid in kratom plants, is a partial μ-opioid receptor agonist that exhibits pain-blocking effects in animal studies, about 66 times less potent than morphine, according to a 2016 paper in the Journal of Medicinal Chemistry. Studies of mitragynine’s reward and abuse potential are mixed; several animal studies of both whole kratom leaf extract and isolated mitragynine report a rewarding effect, while others do not. According to NIDA, scientists have observed that mitragynine may bind to adrenergic receptors, serotonin receptors, and dopamine receptors, which may be responsible for some of the arousing effects some users report experiencing. 7-OH is a metabolite of mitragynine, and is the alkaloid primarily responsible for the pain-blocking effects of mitragynine due to its conversion into 7-OH in the liver and gut, according to an article in ACS Central Science. Although often undetectable in fresh kratom leaves, oxidation of mitragynine into 7-OH can be achieved through a variety of processes, including drying and processing of kratom leaves, metabolism of mitragynine in the body, or chemical oxidation, according to a 2025 review in Pharmaceutical Biology. According to the FDA’s 2025 review, 7-OH is much more potent than mitragynine. Receptor binding assays demonstrate that 7-OH has a 7- to 15-fold higher affinity for μ-opioid receptors than mitragynine, and functional activation assays reveal a 4- to 40-fold increase in potency. According to a 2016 paper in the Journal of Medicinal Chemistry, 7-OH is a powerful analgesic when administered subcutaneously in animal pain-blocking tests—over 350 times more effective than mitragynine and five times more effective than morphine. The 2025 FDA report also summarizes behavioral studies in animals that suggest that 7-OH is a rewarding, habit-forming substance, similar to other opioids. Given this pharmacological profile and potential for abuse, 7-OH has been declared a dangerous substance by the FDA, which warned consumers in 2025 that products containing 7-OH can cause serious harm and should be avoided. Like all drugs, the effects of a kratom product also depend on the amount taken, potency, formulation of the product, the way it is ingested, other drugs in a person’s system, a person’s underlying medical conditions, and a person’s previous experience with the substance, according to NIDA.
- Labeling, packaging, and consumer safety concerns. No specific testing, labeling, or warning is required for kratom products (see “Federal regulation of kratom” section below), meaning that consumers may not be aware of the specific alkaloid blends or dosages contained in a given product. Given the differences in potency and risk of dependence, the conflation of products containing kratom alkaloid extracts with botanical kratom has been highlighted as a safety concern by the FDA. One 2025 study of 7-OH supplemented products in Drug and Alcohol Dependence found that 92% were advertised as kratom, potentially misleading consumers about the potency of the product. Another 2025 market analysis in Substance Use and Misuse revealed that fewer than half of kratom product descriptions that contained mitragynine pseudoindoxyl (a derivative of 7-OH) mentioned an increased risk of intoxication, tolerance, dependence, withdrawal, or addiction. The formats and packaging of some kratom products may also be appealing to children; the 2025 Drug and Alcohol Dependence market review of products containing mitragynine pseudoindoxyl found that 69% used child-appealing flavors or scents and 63% used bright colors in packaging or labeling.
- Adverse events and fatalities. A 2021 analysis in Pharmacotherapy of 935 single-substance kratom exposure cases reported to National Poison Control between 2011 and 2018 found that most exposures occurred via oral ingestion—typically as tablets, capsules, or powder—with the most frequently reported adverse effects including agitation, rapid heartbeat, drowsiness, and vomiting. Although rare, severe adverse effects included seizures, withdrawal, hallucinations, respiratory depression, coma, and cardiac or respiratory arrest. A more recent analysis in the FDA’s 2025 report of 53 human exposures to 7-OH in the National Poison Data System from February to April 2025 found that the majority of cases (37) were single-substance exposures. Of the single-substance exposures, 35% resulted in “moderate clinical outcomes,” a designation used by poison control centers that indicates pronounced, prolonged, or systemic issues that require treatment but are not life-threatening (i.e., acid-base disturbances, disorientation, isolated and brief seizures, treatable blood pressure changes, or acute liver injury). Five of the single-substance exposure cases were children under 18 years of age. According to a 2026 report from the National Drug Early Warning System, from January 1, 2023 to April 30, 2026, 3,672 suspected nonfatal overdose emergency medical services (EMS) encounters involving 7-OH, mitragynine, or kratom use were recorded nationally. El Dorado and Placer counties in California had some of the highest 7-OH, mitragynine, or kratom-related EMS encounters, at approximately 0.5 per 10,000 people. Trend analysis shows that nationally, kratom-related EMS encounters increased from January 2023 to February 2025, rose sharply from March 2025 to September 2025, and increased again from December 2025 to April 2026.
Reports of deaths resulting from kratom are rare, which may be partially attributable to the fact that kratom alkaloids are not commonly included in toxicology panels, according to a review in Pharmaceutical Biology. An international study of 156 deaths involving kratom published in 2019 in the Journal of Psychopharmacology revealed the vast majority of these deaths occurred in young white males with a history of drug use. Kratom was the sole substance implicated in 27 of these cases, with cause of death most often related to pulmonary or cerebral edema or cardiovascular complications. Polysubstance cases involving kratom were more common, particularly in combination with other opioids, benzodiazepines, and recreational stimulants. A Centers for Disease Control and Prevention report on overdose deaths from 2016 to 2017 identified kratom in 0.56% of deaths (152 total). Nearly 60% of these deaths were determined to be caused by kratom, including seven for which kratom was the only substance detected in postmortem toxicology reports. The FDA’s 2025 review on 7-OH reports that between 2023 and 2025, the Drug Enforcement Administration’s (DEA) Toxicology Testing program database identified a threefold increase in fatalities involving kratom or kratom derivatives compared to the three years prior. According to the Los Angeles County Chief Medical Examiner, the county has identified ten deaths to date attributable to 7-OH in otherwise healthy young adults since they started testing for it late in 2025.
- Federal regulation of kratom. According to the FDA, kratom is not lawfully marketed in the U.S. as a drug product, dietary supplement, or food additive in conventional food. No prescription or over-the-counter products containing kratom or kratom alkaloids are currently approved. Kratom is also not appropriate for use as a dietary supplement; the FDA considers kratom a new dietary ingredient, which requires evidence of safety before marketing, and the FDA has concluded that there is currently inadequate information to provide reasonable assurance that the ingredient does not present a significant or unreasonable risk of illness or injury. Therefore, any dietary supplement containing kratom is considered adulterated and thus illegal under the Food, Drug, and Cosmetics Act. Finally, kratom is considered by the FDA to be an unsafe food additive, meaning that adding kratom to any conventional food renders the product adulterated and thus illegal under the Food, Drug, and Cosmetics Act. Accordingly, the FDA has issued import alerts for kratom and has seized kratom products marketed as dietary supplements.
In 2016, the DEA published a notice of intent to temporarily place mitragynine and 7-OH into Schedule I of the Controlled Substances Act, alongside other substances with no accepted medical use and a high potential for abuse. This effort was withdrawn after the DEA received numerous public comments and a bipartisan congressional letter that expressed concerns about overly hasty regulation. In October 2023, legislation was introduced in both the houses of Congress to “protect access to kratom.” According to the CRS report, these bills would have directed the Secretary of Health and Human Services to gather information about kratom and limited the authority to impose regulations on kratom more restrictive than those for foods, dietary supplements, or dietary ingredients. These bills contained a non-preemption clause, which would permit states to either ban or regulate kratom. These bills did not advance, and to date no bills have been introduced in the current congressional session. In recent years, the FDA appears to have directed its enforcement efforts towards products supplemented with 7-OH. In 2025, the agency published a technical report on 7-OH, issued consumer warnings, sent warning letters to retailers, and conducted seizures of 7-OH-containing products. According to a July 2025 press release from the FDA, the FDA formally recommended that the DEA move 7-OH to Schedule I.
- State regulation of kratom. According to a Legislative Analysis and Public Policy Association report, as of January 2026, 30 states and the District of Columbia regulate kratom or its components in some manner. In seven states (Alabama, Arkansas, Connecticut, Indiana, Louisiana, Vermont, and Wisconsin), both mitragynine and 7-OH are controlled substances, while the others regulate the possession, sale, or manufacture of kratom products. Within these states, most restrict kratom sales to adults 21 years of age or older, although seven states restrict kratom sales to those over 18. The legality of 7-OH also varies in these states: while Ohio and Florida have scheduled 7-OH as a controlled substance, eleven states have banned the sale of products containing 7-OH at greater than 1% to 2% of the product’s alkaloid content (Arizona, Colorado, Georgia, Kentucky, Maryland, Mississippi, Oklahoma, Rhode Island, South Dakota, Texas, and Utah) or which contain synthetic 7-OH (Nebraska, Tennessee, and South Carolina). Twenty states, including California, do not have laws regulating kratom.
- Kratom regulation in California. While there is no specific California statute on kratom, the Sherman Law regulates the manufacturing, processing, labeling, advertising, and sale of food, drugs, and cosmetics under the administration and enforcement of CDPH in accordance with the Federal Food, Drug, and Cosmetic Act. CDPH, like the FDA, treats kratom-containing products as adulterated and thus illegal to sell for consumption. In January 2026, CDPH issued a memo to licensed tobacco retailers regarding a “Prohibition on the Sale of Kratom and 7-OH Products,” stating that the retail and online sale of kratom and 7-OH is illegal under Health and Safety Code §110555 (adulterated food). This letter does not make a distinction between leaf kratom and 7-OH containing products. According to CDPH, the department has seized more than $5 million in kratom and 7-OH products statewide and continues enforcement action, including retailer education, warnings, inspections, and legal actions, in collaboration with the California Department of Alcoholic Beverage Control and CDTFA.
CDPH’s Center for Environmental Health is responsible for enforcing the Sherman Law, including product testing and seizure, along with certain counties with delegated enforcement authority (Los Angeles, Orange, and San Bernardino). Additionally, the California Retail Food Code provides counties and other local environmental health departments with authority to enforce food laws, including preventing the sale of adulterated food. However, the Retail Food Code only applies to retail food facilities, leaving most local public health agencies without the authority to enforce prohibitions on the sale of specific ingredients at gas stations and other locations.
To address this limited enforcement capacity based on state law, numerous counties and cities have enacted local ordinances to regulate or prohibit the sale of kratom and 7-OH. For example, Riverside County, Fresno County, and Orange County prohibit the sale and distribution of kratom products to those under 21 and prohibit products that contain more than 2% 7-OH by alkaloid fraction. The cities of Oceanside and Jurupa Valley prohibit the sale, distribution, and possession of all kratom products, and Newport Beach prohibits the sale and distribution of kratom leaf and synthetic alkaloid products. The City of San Diego defines mitragynine and 7-OH as novel psychoactive drugs and has prohibited the sale, distribution, or possession of these products.
- Double referral. This bill is double referred. Should it pass out of this committee, it will be referred to the Senate Committee on Revenue and Taxation.
- Related legislation. AB 634 (Jeff Gonzalez) prohibits a person or entity from manufacturing, distributing, or offering for sale in this state a product that contains tianeptine. Provides that a party found liable for a violation of is liable for a civil penalty brought by the Attorney General, a city attorney, or county counsel, not to exceed $2,500 for the first violation and not to exceed $5,000 for each subsequent violation. AB 634 is set to be heard in this Committee on June 17, 2026.
- Prior legislation. AB 8 (Aguiar-Curry, Chapter 248, Statutes of 2025) requires products containing concentrated cannabinoids other than CBD isolate that are derived from industrial hemp to comply with provisions of the Medicinal and Adult-Use Cannabis Regulation and Safety Act, requires out-of-state hemp manufacturers to register with the state, reverts the cannabis excise tax rate to 15%, and expands the authority for state and local enforcement agencies to inspect, seize, and destroy unlawful cannabis products.
AB 2217 (Weber of 2024) would have prohibited a person or entity from manufacturing, selling, delivering, distributing, holding, or offering for sale, in commerce a food product for human consumption that contains tianeptine. AB 2217 would have made a violation of these provisions punishable by a civil penalty not to exceed $5,000 for a first violation and not to exceed $10,000 for each subsequent violation, upon an action brought by the Attorney General, a city attorney, a county counsel, or a district attorney. AB 2217 was not heard in the Assembly Health Committee.
AB 2365 (Haney of 2024) would have enacted the Kratom Consumer Protection Program to provide a regulatory structure for kratom products that would have required manufacturers and distributors to register with CDPH, adhere to certain requirements that include having products tested, and prohibit the sale to persons under 21. AB 2365 was held on the Senate Appropriations Committee suspense file.
AB 2223 (Aguiar-Curry of 2024) would have permitted cannabis licensees to manufacture, distribute, or sell products that contain industrial hemp, and established additional restrictions on industrial hemp products containing tetrahydrocannabinol (THC) or comparable cannabinoids. AB 2223 was held on the Senate Appropriations Committee suspense file.
AB 45 (Aguiar-Curry, Chapter 576, Statutes of 2021) establishes a regulatory structure in CDPH for food, beverage and cosmetic products containing industrial hemp, and limited these products to containing no more than 0.3% concentration of THC.
SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017) establishes a single system of administration for cannabis laws in California, combining the Medicinal Cannabis Regulation and Safety Act with the Adult Use of Marijuana Act to create the MAUCRSA.
- Support. The California Narcotic Officers’ Association and individual member law enforcement groups write that, in the absence of state or federal regulation of kratom, this bill establishes common sense restrictions on unregulated natural kratom and its dangerous derivative, synthesized 7-hydroxymitragynine (7-OH) products. They make a distinction between kratom, which has been consumed traditionally for its mild energy and analgesic properties, and 7-OH products, which contain predominately synthetic 7-OH and poses risks of addiction, toxicity, and misuse. They share that 7-OH products are highly addictive with the potential for overdose and opioid withdrawal symptoms upon cessation of use. These groups believe this bill will better protect consumers and youth from dangerous products that have resulted in addiction and death in California and across the country.
- Support if amended. The Global Kratom Coalition, an alliance of leaf kratom consumers, experts, and industry leaders, are in strong support of working to enact common sense regulations on natural kratom products while ensuring dangerous synthetic and semi-synthetic products, like concentrated synthetic 7-OH products, are no longer allowed to be sold. However, they believe there are still technical issues that require additional work and urge the Committee to ensure that this bill provides adequate safety measures for California consumers without placing undue burdens on natural kratom vendors.
- Opposition. A coalition letter from the Hispanic Leadership Fund, Taxpayers’ Protection Alliance, Consumer Choice Center, Students for Sensible Drug Policy, Consumer Action for a Strong Economy, Families for America, and End It for Good write that despite over 700 deaths listed on the FDA Adverse Event Reporting System associated with mitragynine, this bill singles out concentrated 7-OH products for an effective prohibition. These groups call for a non-criminalized regulatory framework that prioritizes consumer protections for all kratom products, including removing kratom products from any retail establishment that is not 21 and up, age verification, licensing requirements, labeling standards, independent testing, and transparent reporting of potency and ingredients, to preserve access to safer and more affordable options for those seeking wellness or struggling with addiction. The California Retail and Distribution Fairness Association writes that this bill would eliminate access to products that many Californians use responsibly, potentially pushing consumers toward more dangerous alternatives. This bill would also negatively impact small businesses throughout California, including smoke shops, distributors, and manufacturers that have invested substantial resources into complying with existing regulations and serving their customers responsibly. Infused Partners, a kratom consulting firm, writes that this bill, while intended to create a regulatory structure for kratom, eliminates the entire kratom market due to the flavor restrictions and mitragynine caps that require kratom to sold in costly packaging. They highlight that this bill incentivizes the sale of dangerous 7-OH derivatives and that prohibition-based approaches can drive consumers toward these more dangerous substances such as MGM-15. Individual kratom and 7-OH consumers also write to state that they use these products to manage chronic pain and that the drugs provide a sense of wellbeing. Some say that by using kratom, they can avoid using physician-prescribed opioids or illicit substances, and one individual reported a reduction in their marijuana and alcohol use with kratom and 7-OH use. Consumers claim a ban on 7-OH products would decrease their quality of life and ability to function as productive members of their families and communities.
- Oppose unless amended. The Holistic Alternative Recovery Trust writes that this bill creates a rushed and incomplete regulatory structure for kratom and 7-OH that undermines state and federal action, leaves some synthetic kratom analogs completely unregulated, and creates a market advantage for some industry groups over others. They oppose the alkaloid caps that effectively ban 7-OH products specifically and encourage amendments that focus the bill on child safety and allows more time to develop a more comprehensive regulatory structure. Kreleaf, an online kratom retailer, writes that if this bill passes, many thousands of Californians will die because 7-OH products are a lifeline for those escaping opioid addiction and pain. By implementing an arbitrary 0.57mg cap on 7-OH per package, this bill risks driving consumers back to illicit opioids like fentanyl and heroin. The California Statewide Law Enforcement Association writes that allowing kratom products to remain available while banning only one or some of its active compounds creates a significant loophole that will undermine enforcement efforts and continue to expose consumers, especially minors, to harmful substances. Furthermore, they share that in their enforcement experience, many entities involved in the manufacture and distribution of synthetic intoxicants operate underground or unlicensed facilities and suggest that revenue projections associated with registration fees may fall short as businesses relocate operations out of state or shift production to unregistered facilities. They request that this bill be amended to clearly and explicitly prohibit both kratom and 7-OH to align the bill with the CDPH’s position and ensure a consistent, enforceable framework that fully addresses the risks at issue.
- Letter of concern. The Reason Foundation states that while they applaud the decision to reject an outright prohibition of kratom, the per-package limits in this bill are arbitrary and unworkable, effectively amounting to a category-wide product ban. They state that there is, on average,16mg mitragynine and 0.1mg 7-OH in each gram of kratom, and that kratom products are often sold in bulk 28g packages, meant to be consumed over an extended period of time, which would be prohibited by this bill. They are concerned such caps will incentivize the proliferation of small, maximum-potency, disposable, single-serving kratom products, rather than kratom products designed for adults to use at home over time. They believe the alkaloid caps in this bill should instead be 40mg of mitragynine and 10mg of 7-OH per serving, which they claim reflects a science-based per-serving limit. The Cato institute writes that although this bill’s testing requirements, labeling standards, and age restrictions can help protect consumers, the elimination of a legal market for concentrated 7-OH products is unlikely to eliminate demand and may push consumers towards unregulated drugs. They write that California can better protect public health through regulation, education, harm-reduction measures, and access to treatment than through policies that effectively prohibit products for which consumer demand remains strong.
- Permitting sales of kratom is counter to current position of FDA. A comprehensive regulatory structure around kratom products may signal that the state deems these products to be sufficiently safe for those 21 years of age or older, with an acceptable level of risk for dependence or misuse. Given that the FDA has determined there is insufficient safety data to support the marketing of kratom products even as dietary supplements, it may be premature for the state to take a position on the safety of kratom products. Similarly, the concentration limits established in this bill may be perceived as recommended serving sizes or safe dosages. This bill would put the state of California in the position of authorizing the sale of products both the FDA and CDPH have determined cannot be legally sold for human consumption.
SUPPORT AND OPPOSITION:
Support: Arcadia Police Officers' Association
Brea Police Association
Burbank Police Officers' Association
California Association of School Police Chiefs
California Coalition of School Safety Professionals
California Narcotic Officers' Association
California Reserve Peace Officers Association
Claremont Police Officers Association
Corona Police Officers Association
County of Santa Barbara
Culver City Police Officers' Association
Fullerton Police Officers' Association
League of California Cities
Los Angeles School Police Management Association
Los Angeles School Police Officers Association
Murrieta Police Officers' Association
Newport Beach Police Association
Palos Verdes Police Officers Association
Placer County Deputy Sheriffs' Association
Pomona Police Officers' Association
Riverside Police Officers Association
Riverside Sheriffs' Association
Several individuals
Oppose: California Retail and Distribution Fairness Association
California Statewide Law Enforcement Association (unless amended)
Consumer Action for a Strong Economy
Consumer Choice Center
End It for Good
Families for America
Hispanic Leadership Fund
Holistic Alternative Recovery Trust (unless amended)
Infused Partners
Kreleaf (unless amended)
Students for Sensible Drug Policy
Taxpayers Protection Alliance
Several individuals
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1088
Author:(Bains)
As Amended Ver:April 21, 2025
Majority vote
SUMMARY
Adds kratom products and products containing 7-hydroxymitragynine (7-OH products), as defined, to the Sherman Food, Drug, and Cosmetic Law (Sherman Law). Prescribes specified quantities of alkaloids present in kratom products and 7-OH products. Prohibits the sale of kratom products and 7-OH products to those under 21 years of age. Requires the packaging of kratom products and 7-OH products to be child resistant and prohibits the sale and manufacture of a kratom product or 7-OH product that is attractive to children.
Major Provisions
COMMENTS
Background. Kratom (Mitragyna speciosa) is a tree in the coffee family, found in Thailand and neighboring countries. These leaves are crushed and then smoked, brewed with tea, or placed into gel capsules. Kratom has a long history of use in Southeast Asia, where it is commonly known as thang, kakuam, thom, ketum, and biak. Traditionally, in Southeast Asia, people have chewed its leaves or made them into a tea that is used to fight fatigue and improve work productivity. Kratom has also traditionally been used during religious ceremonies and to treat symptoms such as pain and diarrhea, sometimes as a substitute for opium. In this bill, kratom leaf refers to the leaf of a kratom plant. The alkaloid content refers to the sum of the various alkaloids that are present in the leaf material that contribute the effect of the plant, including mitragynine, paynantheine, speciogynine, speciociliatine, and 7-hydroxymitragynine.
Effects of kratom usage. Kratom leaves contain two major psychoactive ingredients, mitragynine and 7-hydroxymitragynine, which interact with opioid receptors in the brain. People who use kratom have reported both stimulant-like effects (increased energy, alertness, rapid heart rate) and effects like those of opioids and sedatives (relaxation, pain relief, confusion). Per the United States Drug Enforcement Administration (DEA), consumption of kratom tree leaves produces a stimulant effect in low doses, and a sedative effect in high doses. Consumption of kratom in high doses can also lead to psychotic symptoms, and psychological and physiological dependence.
According to the National Institutes of Health Center for Complementary and Integrative Health (NCCIH), people may use kratom to try to overcome opioid addiction, kratom itself may have the potential to be addictive. People have reported using kratom to manage opioid withdrawal symptoms and cravings, and researchers are studying whether kratom is helpful for this purpose. However, kratom has not been shown to be safe and effective for this or any other medical use. Regular kratom users may experience withdrawal symptoms if they stop using it.
NCCIH notes that a variety of side effects of kratom have been reported. They include mild effects, such as nausea, constipation, dizziness, and drowsiness, and rare but serious effects such as seizures, high blood pressure, and liver problems. Fatal overdoses from kratom alone appear to be extremely rare. The use of kratom in combination with other drugs has been linked to deaths and severe adverse effects such as liver problems. More research is needed on drug interactions involving kratom.
NCCIH highlights that the long-term effects of kratom use are not well understood. Harmful contaminants such as heavy metals and disease-causing bacteria have been found in some kratom products.
According to the DEA, the abuse of kratom has increased markedly in recent years. Several cases of psychosis resulting from use of kratom have been reported, where individuals addicted to kratom exhibited psychotic symptoms, including hallucinations, delusion, and confusion.
Research on kratom use. According to a 2019 study titled, "Current perspectives on the impact of Kratom use", the national poison center reporting database documented 1,807 calls related to kratom exposure from 2011 to 2017. The Centers for Disease Control and Prevention analyzed data on unintentional and undetermined opioid overdose deaths from the State Unintentional Drug Overdose Reporting System. Kratom was detected on postmortem toxicology testing in 152 cases of 27,338 overdose deaths from data collected from 11 states from July 2016 to June 2017 and 27 states from July 2017 to December 2017. Kratom was identified as the cause of death by a medical examiner in 91 of the 152 kratom-positive deaths, but was the only identified substance in just seven of these cases. Presence of additional substances in these seven kratom-only cases cannot be ruled out. The co-occurring substances in the 91 cases where kratom was identified as the cause of death include fentanyl (including analogs), heroin, benzodiazepines, prescription opioids, cocaine, and alcohol. Multi-substance exposures involving kratom, predominantly in combination with opioids, are associated with a greater odds ratio of admittance to a health care facility and occurrence of a serious medical outcome when compared to kratom-only exposure.
These data highlight that kratom use is associated with a complex population of poly-drug users and especially with opioid use disorder. The data further suggests that a deeper investigation into the toxicity of kratom is needed, especially focusing on drug–herb interactions.
Please see the Assembly Health Committee analysis for a more detailed discussion of kratom at a national level and in other states.
Kratom in California. Some estimates show that nearly 25% of all kratom sales in the United States are in California. In March 2024, the city of Newport Beach approved an ordinance to prohibit the sale and distribution of kratom. The City of San Diego and Oceanside banned the use and sale of kratom in 2016. It has been reported that some manufacturers have created stronger and more potent kratom concentrates to put into their products. According to a 2023 study titled, "Kratom availability in California vape shops," kratom was available in two-thirds of vape-and-smoke shops throughout California.
Attractiveness to children. The Kratom Consumer Advisory Council (KCAC) put out a position statement in October 2024 highlighting their concerns regarding the marketing of kratom products that may appeal to children intentionally or unintentionally. KCAC noted that some products are sold in forms resembling popular candies, such as gummies, lollipops, chocolate bars, and cookies. These products often feature bright colors, mascots, and flavors that could attract young children or be mistaken for regular candy. KCAC noted that the ease of access to these products and their resemblance to well-known candy items raise concerns about accidental ingestion by younger children. This bill prohibits kratom products sold or distributed from being attractive to children.
What is 7-OH? According to a 2019 study titled, "7-Hydroxymitragynine is an Active Metabolite of Mitragynine and a Key Mediator of its Analgesic Effects," mitragynine is the major active alkaloid found in kratom, and that it is converted to the much more potent mu-opioid receptor agonist 7-OH in the liver. The study found that brain concentrations of 7-OH are sufficient to explain most or all of the opioid-receptor-mediated analgesic activity of mitragynine. At the same time, mitragynine was found in the brains of mice at very high concentrations relative to its opioid receptor binding affinity, suggesting that it does not directly activate opioid receptors. The results suggest a metabolism-dependent mechanism for the analgesic effects of mitragynine. This bill prohibits the sale of a kratom product or 7-OH product with a level of 7-hydroxymitragynine that is greater than 2% of the total kratom alkaloids in the product.
According to the Author
As a physician specializing in addiction treatment, I have grown increasingly concerned about the use of Kratom and especially its derivative 7-OH. We have reached the point that state and federal regulators can no longer ignore these products. Until the federal government does its job, California must act to protect our residents and especially our children. AB 1088 is a reasonable first step to age gate these products as we consider additional regulatory protections to put in place.
Arguments in Support
The California Narcotic Officers' Association (CNOA) supports this bill and writes, synthesized 7-hydroxymitragynine (7-OH) products, referred to as "legal morphine," are developed from kratom and have become 30 times more potent than morphine. CNOA continues that 7-OH produces opioid-like effects and can cause fatal overdoses, making their abuse a serious public health and safety concern. CNOA continues other adverse effects of 7-OH include psychotic symptoms, and psychological and physiological dependence. CNOA notes that natural kratom products generally contain no more than 66% of mitragynine as the main alkaloid and 2% of 7-hydroxymitragynine in the alkaloid fraction of the extract. CNOA continues that a number of states including Arizona, Oklahoma, Texas, and Utah have enacted bans on synthetic 7-OH exceeding 2% of total alkaloid content in products. CNOA notes that in California, natural kratom products remain unregulated and unrestricted. CNOA states that any one of any age can purchase kratom and synthesized 7-OH products. CNOA states that this addresses safety concerns about natural kratom and 7-OH products by implementing some common-sense measures to protect the public and our youth by establishing a: minimum age of 21 to purchase; requirement for child-resistant packaging; ban on marketing that appeals to children; limit on 7-OH content not to exceed 2% of the product's total alkaloid content. CNOA concludes that AB 1088 will protect better consumers and our youth from dangerous products that have resulted in addiction and death in our state and across the country.
Arguments in Opposition
The Holistic Alternative Recovery Trust (HART) opposes this bill on the grounds that a cap of 2% of the total alkaloids allowed in a kratom leaf is so de minimis as to be meaningless when manufacturing a 7-OH product. HART directs readers to their April 1, 2025 letter where they expanded on their concerns. Highlights from the previous letter: HART's belief that exploring the potential applications of 7-OH could contribute to discussions on addressing opioid misuse and strategies; evolving research on 7-OH; and concerns that the percentage cap is a fatally-flawed measure noting that bad actor manufacturers who wish to create a high mg 7-OH product can easily adhere to the percentage cap and add the corresponding amount of mitragynine, thereby releasing a dangerous but compliant product. HART concludes by stating that it hopes that a realistic approach to regulating 7-OH that is focused on the potential benefits to California consumers.
FISCAL COMMENTS
According to the Assembly Committee on Appropriations, the California Department of Public Health (DPH) estimates annual General Fund costs of $2.63 million beginning in fiscal year (FY) 2026-27 for 13 full time staff positions to conduct inspections, ensure compliance, conduct investigations, test kratom products, and compile and provide educational materials to industry. DPH anticipates additional General Fund costs of $829,000 in FY 2026-27 for initial peace officer training and laboratory supplies for testing.
VOTES
ASM HEALTH: 16-0-0
YES: Bonta, Chen, Addis, Aguiar-Curry, Rogers, Carrillo, Flora, Mark González, Krell, Patel, Patterson, Celeste Rodriguez, Sanchez, Schiavo, Sharp-Collins, Stefani
ASM ENVIRONMENTAL SAFETY AND TOXIC MATERIALS: 7-0-0
YES: Connolly, Ellis, Bauer-Kahan, Castillo, Lee, McKinnor, Papan
ASM APPROPRIATIONS: 14-0-1
YES: Wicks, Arambula, Calderon, Caloza, Dixon, Elhawary, Fong, Mark González, Hart, Pacheco, Pellerin, Solache, Ta, Tangipa
ABS, ABST OR NV: Sanchez
UPDATED
VERSION: April 21, 2025
CONSULTANT: Eliza Brooks / HEALTH / (916) 319-2097 FN: 0000745
Date of Hearing: May 21, 2025
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 1088
Author:(Bains) – As Amended Ver:April 21, 2025
Policy Committee: | Health | Vote: | 16 - 0 |
Environmental Safety and Toxic Materials | 7 - 0 | ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill adds kratom products and products containing 7-hydroxymitragynine (7-OH products) to the Sherman Food, Drug, and Cosmetic Law and prohibits the sale of kratom products and 7-OH products to persons under 21 years of age. The bill also requires the packaging of kratom products and 7-OH products to be child resistant and prohibits the sale of a kratom product or 7-OH product that is attractive to children, as defined, or that contains a level of 7-OH that exceeds 2% of the total kratom alkaloids in the product.
Specifically, this bill:
- Defines, for purposes of this bill, the following terms: “7-OH product,” “attractive to children,” “kratom leaf,” “kratom leaf extract,” “kratom product,” and “total kratom alkaloids.”
- Requires packaging of a kratom product or a 7-OH product offered for retail sale to be child resistant for the life of the product and specifies two types of packages considered child resistant for the purposes of this bill.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product or 7-OH product to a person under 21 years of age.
- Requires an online retailer or marketplace of a kratom product or 7-OH product to implement an age-verification system to ensure compliance with item 3, above.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product or 7-OH product that is attractive to children.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product or 7-OH product with a level of 7-hydroxymitragynine that is greater than 2% of the total kratom alkaloids in the product.
FISCAL EFFECT:
The California Department of Public Health (CDPH) estimates annual General Fund costs of $2.63 million beginning in fiscal year (FY) 2026-27 for 13 full time staff positions to conduct inspections, ensure compliance, conduct investigations, test kratom products, and compile and provide educational materials to industry.
CDPH anticipates additional General Fund costs of $829,000 in FY 2026-27 for initial peace officer training and laboratory supplies for testing.
COMMENTS:
- Purpose. According to the author:
As a physician specializing in addiction treatment, I have grown increasingly concerned about the use of kratom and especially its derivative 7-OH. We have reached the point that state and federal regulators can no longer ignore these products. Until the federal government does its job, California must act to protect our residents and especially our children. AB 1088 is a reasonable first step to age gate these products as we consider additional regulatory protections to put in place.
- Background. Kratom is a tree in the coffee family, found in Thailand and neighboring countries, where kratom leaves are crushed and then smoked, brewed with tea, or placed into gel capsules. Kratom has a long history of traditional use in Southeast Asia, where it has been used during religious ceremonies, to treat symptoms such as pain and diarrhea, and as a substitute for opium. Over the past decade, kratom use has become increasingly popular in the US. Many US users have reported that consumption of kratom preparations is an effective treatment for pain and for mood and anxiety disorders, particularly in cases where other available treatments have either failed or elicited intolerable side effects. Many users also report using kratom to stop or reduce consumption of prescription or illicit opioids. However, there has been little clinical research on kratom.
- Support. According to a coalition of law enforcement organizations:
Synthesized [7-OH] products, referred to as 'legal morphine,' are developed from kratom and have become 30 times more potent than morphine…Natural kratom products generally contain no more than 66% of mitragynine as the main alkaloid and 2% of [7-OH] in the alkaloid fraction of the extract. A number of states…have enacted bans on synthetic 7-OH exceeding 2% of total alkaloid content in products…AB 1088 addresses safety concerns about natural kratom and 7-OH products by implementing common-sense measures to protect the public and our youth…
- Opposition. The Holistic Alternative Recovery Trust (HART) argues that a cap of 2% of the total alkaloids allowed in a kratom leaf is so de minimis as to be meaningless when manufacturing a 7-OH product, and is a fatally flawed measure because bad actor manufacturers who wish to create a high mg 7-OH product can easily adhere to the percentage cap and add the corresponding amount of mitragynine, thereby releasing a dangerous but compliant product. HART contends that exploring the potential applications of 7-OH could contribute to discussions on addressing opioid misuse.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 29, 2025
ASSEMBLY COMMITTEE ON ENVIRONMENTAL SAFETY AND TOXIC MATERIALS
Damon Connolly, Chair
ABPCA Bill Id:AB 1088 (
Author:Bains) – As Amended Ver:April 21, 2025
SUBJECT: Public health: kratom
SUMMARY: Adds kratom products and products containing 7-hydroxymitragynine (7-OH), as defined, to the Sherman Food, Drug, and Cosmetic Law (Sherman Law); prohibits the sale of kratom products and 7-OH products to persons under 21 years of age; requires the packaging of kratom products and 7-OH products to be child resistant; prohibits the sale of a kratom product or 7-OH product that is attractive to children, or that contains a level of 7-OH that exceeds 2% of the total kratom alkaloids in the product. Specifically, this bill:
- Defines, for purposes of this bill, the following terms:
- "7-OH product" to mean a product containing 7-hydroxymitragynine;
- "Attractive to children" to mean any of the following:
- Use of images that are attractive to children, including but not limited to images of any of the following, except as part of required health warnings:
- Cartoons, toys, or robots;
- Any real or fictional humans;
- Fictional animals or creatures; and,
- Fruits or vegetables, except when used to accurately describe ingredients or flavors contained in a product.
- Likeness to images, characters, or phrases that are popularly used to advertise to children;
- Imitation of candy packaging or labeling, or other packaging and labeling of cereals, sweets, chips, or other food products typically marketed to children;
- The terms "candy" or "candies" or variants in spelling such as "kandy" or "kandee";
- Brand names or close imitations of brand names of candies, cereals, sweets, chips, or other food products typically marketed to children;
- Any other image or packaging that is easily confused with commercially available foods that do not contain kratom and are typically marketed to children;
- Anything else that the California Department of Public Health (CDPH) determines in regulation to be attractive to children; and,
- Anything else that is attractive to children in light of all relevant facts and circumstances;
- Use of images that are attractive to children, including but not limited to images of any of the following, except as part of required health warnings:
- "Kratom leaf" to mean the leaf of the kratom plant, also known as Mitragyna speciosa, in any form;
- "Kratom leaf extract" to mean the material obtained by extraction of kratom leaves by any means;
- "Kratom product" to mean a product consisting of kratom leaf, kratom leaf extract, or both; and,
- "Total kratom alkaloids" to mean the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-OH in a kratom product.
- Requires packaging of a kratom product or a 7-OH product offered for retail sale to be child resistant for the life of the product; specifies that both of the following packages are considered child resistant for the purposes of this bill:
- A package that has been certified as child resistant under the requirements of the federal Poison Prevention Packaging Act of 1970 (Act) and any regulations promulgated pursuant to the Act; and,
- Plastic packaging that is at least four mils thick (one mil is a thousandth of an inch) and heat sealed without an easy-open tab, dimple, corner, or flap, provided that the package maintains its child resistance throughout the life of the product.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product or 7-OH product to a person under 21 years of age; requires an online retailer or marketplace of a kratom product or 7-OH product to implement an age-verification system to ensure compliance with this prohibition.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product or 7-OH product that is attractive to children.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product or 7-OH product with a level of 7-OH that is greater than 2% of the total kratom alkaloids in the product.
EXISTING LAW:
- Establishes the state's Sherman Law, administered by CDPH, which regulates the manufacture, packaging, labeling, and advertising of food, drugs, and cosmetics. (Health and Safety Code (HSC) § 109875-111929.4)
- Establishes penalties for violations of the Sherman Law, including a fine of up to $1,000, or up to $10,000 for repeated violations. (HSC § 111825)
- Prohibits any manufacturer, wholesaler, retailer, or other person from selling, transferring, or otherwise furnishing a dietary supplement containing either of the following to a person under 18 years of age:
- A dietary supplement containing an ephedrine group alkaloid; or
- A dietary supplement containing any of the following: androstanediol, androstanedione, androstenedione, norandrostenediol, norandrostenedione, or dehydroepiandrosterone. (HSC § 110423.2)
- Establishes a regulatory structure in CDPH, under the Sherman Law, for food, beverage, and cosmetic products containing industrial hemp, and limits these products to containing no more than 0.3% concentration of tetrahydrocannabinol (THC); prohibits industrial hemp from including cannabinoids produced through chemical synthesis. (HSC § 111920, et seq.; HSC § 111920(f))
- Enacts the Medicinal and Adult-Use Cannabis Regulation and Safety Act to establish a comprehensive system to control and regulate the cultivation, distribution, transport, storage, manufacturing, processing, and sale of both medicinal cannabis and cannabis products, and adult-use cannabis and cannabis products for adults 21 years of age and over, regulated by the Department of Cannabis Control. (Business and Professions Code § 26000, et seq.)
FISCAL EFFECT: Unknown.
COMMENTS:
Need for the bill: According to the author:
"As a physician specializing in addiction treatment, I have grown increasingly concerned about the use of kratom and especially its derivative 7-OH. We have reached the point that state and federal regulators can no longer ignore these products. Until the federal government does its job, California must act to protect our residents and especially our children. AB 1088 is a reasonable first step to age gate these products as we consider additional regulatory protections to put in place."
What is kratom? Kratom (Mitragyna speciosa) is a tree in the coffee family, found in Thailand and neighboring countries, where kratom leaves are crushed and then smoked, brewed with tea, or placed into gel capsules. Kratom has a long history of traditional use in Southeast Asia, where it has been used during religious ceremonies, to treat symptoms such as pain and diarrhea, and as a substitute for opium.
What are kratom alkaloids? Kratom leaves contain a number of chemicals called alkaloids. According to the National Cancer Institute (housed in the National Institutes of Health), alkaloids are a large group of substances that contain nitrogen and are found in plants and in some fungi. Alkaloids can often be made in a laboratory, and include well-known chemicals with neuropsychological effects, including nicotine, caffeine, and codeine. Some alkaloids are also used as medications to treat diseases such as cancer. According to the 2019 study, "7-Hydroxymitragynine is an Active Metabolite of Mitragynine and a Key Mediator of its Analgesic Effects," published in the American Chemical Society's ACS Central Science journal (2019 ACS Study), the major active alkaloid found in kratom is mitragynine. Studies suggest that mitragynine is converted into the metabolite 7-OH, another alkaloid, in the liver. Authors of the 2019 ACS Study cite research showing that mitragynine typically constitutes 1-2% of the dry leaf mass and up to approximately two-thirds of the total alkaloid content. 7-OH occurs in much lower concentrations in the kratom leaf, typically less than 0.05% of the dried leaf mass. The other predominant alkaloids in kratom leaf are speciociliatine, speciogynine, and paynantheine.
Kratom use and alkaloid effects: In a description of kratom use, the 2019 ACS Study states:
"Over the past decade, kratom use has become increasingly popular in the United States (US). Many thousands of US users have reported that consumption of kratom preparations (most often in the form of dried, powdered leaf material) is an efficacious treatment not only for physical pain, but also for mood and anxiety disorders, particularly in cases where other available treatments have either failed or elicited intolerable side effects. A significant portion of users have also reported use of kratom as a tool to stop or reduce consumption of prescription or illicit opioids, a potential application that is presently of high interest given the ongoing opioid abuse epidemic in the US. Unfortunately, there have been no controlled clinical studies either examining these alleged therapeutic effects or quantifying any potential risks of kratom use. At the same time, kratom is primarily distributed through unregulated Internet sales and used outside medical supervision."
The study's authors also report that 7-OH is a much more potent opioid receptor agonist (meaning that it is a much stronger activator of systems in the brain that are sensitive to opioids), and that the brain concentrations of 7-OH are "sufficient to explain most or all" of the pain relieving effects of mitragynine, which they posit does not directly activate opioid receptors. In other words, 7-OH seems to be the alkaloid most responsible for kratom's opioid-like effects.
The Mayo Clinic, on its webpage, "Kratom: Unsafe and ineffective," (last updated on June 18, 2024), summarizes some of the reasons that people use kratom; potential challenges with products currently on the market; and possible effects, including adverse effects, from kratom usage:
"People who use kratom report that at low doses, kratom acts as an upper, called a stimulant. That means it makes them more alert and gives them more energy. At higher doses, people who use it report that it reduces pain and makes them feel calm and less anxious, also called a sedative.
Some people take kratom to ease the symptoms of quitting opioids, called withdrawal. Kratom may be easier to get than prescription medicines. But it carries its own risk of addiction.
People who use kratom to relax or to be more social most likely think that kratom is natural and safe because it comes from a plant. But the amount of the active part in kratom leaves can vary greatly. So it's hard to know the effects of a given dose.
Some studies have found that some kratom sellers add more of the active ingredient than kratom naturally has. And because kratom products lack clear labels, it's not possible to know how much kratom people who use it take.
Kratom starts to work in minutes. The effects last a few hours. The more kratom you take, the stronger the effects are.
Depending on the amount of active ingredient in the product and the health of the user, taking kratom can be harmful. There are too few studies to be able to rate the claims about the benefits of kratom."
The Mayo Clinic webpage goes on to state that "kratom hasn't been shown to be safe or to treat any medical conditions" and lists known side effects as including: weight loss, dry mouth, nausea and vomiting, constipation, liver damage, muscle pain, dizziness, drowsiness, hallucinations, delusions, depression, and trouble breathing. In addition, kratom has also been reported to react with other medications, and kratom products have occasionally been found to be contaminated with heavy metals and bacteria. The Mayo Clinic also states that "experts don't know what level of kratom" causes adverse effects.
National poison center data and use of kratom with other drugs: According to the 2019 literature review, "Current perspectives on the impact of Kratom use," published in Substance Abuse and Rehabilitation, the national poison center reporting database documented 1,807 calls related to kratom exposure from 2011 to 2017. The Centers for Disease Control and Prevention analyzed data on unintentional and undetermined opioid overdose deaths from the State Unintentional Drug Overdose Reporting System. Kratom was detected on postmortem toxicology testing in 152 cases of 27,338 overdose deaths from data collected from 11 states from July 2016 to June 2017, and 27 states from July 2017 to December 2017. Kratom was identified as the cause of death by a medical examiner in 91 of the 152 kratom-positive deaths. In seven of these cases, kratom was the only identified substance, although the presence of additional substances in these kratom-only cases could not be ruled out. For cases where kratom was identified as the cause of death, co-occurring substances included fentanyl, heroin, benzodiazepines, prescription opioids, cocaine, and alcohol. According to the authors, the combination of kratom with other substances was associated with an increased probability of admittance to a health care facility and occurrence of a serious medical outcome, when compared to kratom-only exposure. Based on their review, the study's authors conclude that kratom use is "associated with a complex population of poly-drug users and especially with opioid use disorder," and that additional research on kratom's toxicity is needed.
Kratom use among teens: According to the Child Mind Institute, kratom addiction is becoming more common among teens. On its webpage, "Kratom: A legal drug that's dangerously addictive" (last updated on October 30, 2024), the Child Mind Institute states, "It's easy for teens to get kratom in smoke shops and on the internet. One of the reasons they like it is because it doesn't show up on standard drug tests. Only some labs test for kratom, and doing so is expensive." Dr. Mike Milham—a child and adolescent psychiatrist at the Child Mind Institute, and the founding director of the Child Mind Institute's Center for the Developing Brain—states, "High school and college students are surrounded by kratom these days—in smoke shops and on the internet…For students especially, you can imagine the allure of the stimulant effects, but once you start experiencing the euphoria of the opioid aspect, you’re at risk for addiction." On the issue of kratom regulation and safety, Dr. Milham also states: "Making [kratom] completely illegal isn’t necessarily a good idea, because at this point you do have portions of the community that actually are using it to help with opioid withdrawal, and to just make it illegal and take it completely off schedule doesn’t really make sense." Instead, Dr. Milham suggests that the best solution would be to make kratom a Schedule II drug, a classification by the DEA that is applied to medications "with a high potential for abuse, with use potentially leading to severe psychological or physical dependence." Under that classification, kratom could be used in a controlled fashion, with reliable quantities of active ingredients. As noted below, the DEA has not exercised its authority to schedule kratom.
Legal status and regulation of kratom: Below is an overview of the legal status and regulation of kratom, at the national and state levels:
- National level: Kratom is currently legal and accessible online and in stores in many areas of the United States (U.S.). In 2016, the DEA published notice of its intent to place mitragynine and 7-OH in Schedule I on an emergency basis, which would have criminalized possession of kratom and made distribution a felony. However, after receiving numerous comments from some Members of Congress, advocacy groups, and others, the DEA withdrew its notice. The DEA has listed kratom as a Drug and Chemical of Concern, but to date has not exercised its authority to schedule kratom or its active compounds under the federal Controlled Substances Act.
Kratom cannot be lawfully marketed in the U.S. as a drug product, dietary supplement, or a food additive in conventional food. According to the FDA’s webpage, "FDA and Kratom," the FDA has not approved any prescription or over-the-counter drug products containing kratom, or its two main chemical components, mitragynine and 7-OH. Consistent with FDA’s practice regarding unapproved substances, until its agency scientists can evaluate the safety and effectiveness of kratom (or its components) in the treatment of any medical conditions, FDA will continue to warn the public against the use of kratom for medical treatment. The FDA has also concluded from available information, including scientific data, that kratom is a new dietary ingredient for which there is inadequate information to provide reasonable assurance that it does not present a significant or unreasonable risk of illness or injury and, therefore, dietary supplements that are or contain kratom are adulterated under the federal Food, Drug, and Cosmetic Act. In addition, the FDA has determined that kratom, when added to food, is an unsafe food additive, which means that food containing kratom is considered adulterated under federal law.
The FDA has issued a series of import alerts, most recently in July 2023, authorizing its personnel to seize imported kratom products from specified firms without physical inspection. The FDA has also seized kratom products manufactured in the U.S., including an April 2023 seizure of kratom products worth approximately $3 million from an Oklahoma company.
- Other States: Other states have taken a variety of approaches for regulating kratom, including the implementation of bans, age restrictions, dosage caps, and child protections. Below is a summary of different approaches used across states:
- Kratom bans: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin currently ban mitragynine and hydroxymitragynine or 7-OH. Legislators in Indiana, Rhode Island, Wisconsin, and Vermont have introduced bills to replace existing bans with regulations that would permit the sale of kratom products;
- Age restriction: Arizona, Georgia, Illinois, Minnesota, Nevada, Oklahoma, Texas, and Utah ban sales to persons under 18 years of age;
- Strength: Arizona, Oklahoma, Texas, and Utah prohibit sale of products in which 7-OH is greater than 2% of the total alkaloid content; and,
- Marketing to children: Utah prohibits flavoring or packaging that appeals to children and requires child-safe packaging. West Virginia’s recently adopted law requires the commissioner of agriculture to develop similar standards.
- California: In the absence of statewide laws, some municipalities in California have taken steps to regulate kratom. In March 2024, the city of Newport Beach approved an ordinance to prohibit the sale and distribution of kratom. The cities of San Diego and Oceanside banned the use and sale of kratom in 2016.
Concerns regarding attractiveness of kratom products to children: In October 2024, the Kratom Consumer Advisory Council (KCAC)—which is affiliated with the Global Kratom Coalition (self-described as an alliance of kratom consumers, experts, and industry leaders)—released a position statement highlighting concerns regarding the marketing of kratom products in ways that may appeal to children, either intentionally or unintentionally. KCAC notes that some products are sold in forms resembling popular candies, such as gummies, lollipops, chocolate bars, and cookies. These products often feature bright colors, mascots, and flavors that could attract young children or be mistaken for regular candy. KCAC notes that the ease of access to these products and their resemblance to well-known candy items raise concerns about accidental ingestion by younger children.
This bill: Kratom and 7-OH products remain unregulated by the state of California, despite potential risks associated with their use. AB 1088 proposes several guardrails to help protect consumers, by prohibiting the sale of these products to persons under 21 years of age; requiring that packaging for these products be child resistant; prohibiting the sale of products that are attractive to children; and prohibiting the sale of products that contain levels of 7-OH that exceed 2% of the total kratom alkaloids. As noted in the Assembly Health Committee's analysis for AB 1088, the author may wish to consider continued discussions with stakeholders regarding the proposed cap on 7-OH levels, including whether milligrams would be an effective form of measurement.
Arguments in support: According to a coalition of law enforcement organizations:
"Synthesized [7-OH] products, referred to as 'legal morphine,' are developed from kratom and have become 30 times more potent than morphine…Natural kratom products generally contain no more than 66% of mitragynine as the main alkaloid and 2% of [7-OH] in the alkaloid fraction of the extract. A number of states including Arizona, Oklahoma, Texas, and Utah have enacted bans on synthetic 7-OH exceeding 2% of total alkaloid content in products.
In California, natural kratom products remain unregulated and unrestricted. Any one of any age can purchase kratom and synthesized [7-OH] products.
AB 1088 addresses safety concerns about natural kratom and 7-OH products by implementing some common-sense measures to protect the public and our youth by establishing a:
- Minimum age of 21 to purchase
- Requirement for child-resistant packaging
- Ban on marketing that appeals to children
- Limit on 7-OH content not to exceed 2% of the product’s total alkaloid content."
Arguments in opposition: According to the Holistic Alternative Recovery Trust:
"Of greatest concern is a proposed percentage cap on 7-OH in section 111224.8(d)(C) that would create a de facto ban on 7-OH.
The U.S. opioid crisis is the leading public health challenge of the new millennium. There are more than 200 opioid overdoses and poisonings every day—and drug overdose is now the number one cause of death for 18-45 year olds. To address this unprecedented crisis, policymakers and public health officials need to identify new tools for the toolbox…
We agree that a cap on 7-OH in any product may make sense from a consumer protection standpoint, and we are more than willing to have that discussion. However, as the recent debate over hemp products has amply demonstrated, a percentage cap is a fatally flawed measurement. Bad actor product manufacturers who wish to create a high [milligram] 7-OH product can easily adhere to the percentage cap and add the corresponding amount of mitragynine, thereby releasing a potentially dangerous, but compliant, product out into the marketplace."
Related legislation:
- AB 2365 (Haney, 2024). Would have established the Kratom Consumer Protection Program, to provide a regulatory structure for kratom products, as provided. This bill was held on the suspense file in the Senate Appropriations Committee.
- AB 45 (Aguiar-Curry, Chapter 576, Statutes of 2021). Establishes a regulatory structure in CDPH for food, beverage, and cosmetic products containing industrial hemp, and limits these products to containing no more than 0.3% concentration of THC.
- SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017). Establishes a single system of administration for cannabis laws in California, combining the Medicinal Cannabis Regulation and Safety Act with the Adult Use of Marijuana Act, to create the Medicinal and Adult-Use Cannabis Regulation and Safety Act.
REGISTERED SUPPORT / OPPOSITION:
Support
Arcadia Police Officers' Association
Brea Police Association
Burbank Police Officers' Association
California Association of School Police Chiefs
California Coalition of School Safety Professionals
California District Attorneys Association
California Narcotic Officers' Association
California Reserve Peace Officers' Association
Claremont Police Officers Association
Cleanearth4kids.org
Corona Police Officers' Association
Culver City Police Officers' Association
Fullerton Police Officers' Association
Los Angeles School Police Management Association
Los Angeles School Police Officers' Association
Murrieta Police Officers' Association
Newport Beach Police Association
Palos Verdes Police Officers' Association
Placer County Deputy Sheriffs' Association
Pomona Police Officers' Association
Riverside Police Officers Association
Riverside Sheriffs' Association
Santa Ana Police Officers Association
Opposition
Holistic Alternative Recovery Trust
Analysis Prepared by: Naomi Ondrasek / E.S. & T.M. / (916) 319-3965
Date of Hearing: April 22, 2025
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 1088
Author:(Bains) – As Amended Ver:April 21, 2025
SUBJECT: Public health: 7-Hydroxymitragynine.
SUMMARY: Adds kratom products and products containing 7-hydroxymitragynine (7-OH products), as defined, to the Sherman Food, Drug, and Cosmetic Law (Sherman Law). Prescribes specified quantities of alkaloids present in kratom products and 7-OH products. Prohibits the sale of kratom products and 7-OH products to those under 21 years of age. Requires the packaging of kratom products and 7-OH products to be child resistant and prohibits the sale and manufacture of a kratom product or 7-OH product that is attractive to children. Specifically, this bill:
- Defines, for purposes of this section, the following terms:
- “7-OH product” to mean a product containing 7-hydroxymitragynine.
- “Attractive to children” to mean any of the following:
- Use of images that are attractive to children, including but not limited to images of any of the following, accept as part of required health warnings:
- Cartoons, toys, or robots;
- Any real or fictional humans;
- Fictional animals or creatures; and,
- Fruits or vegetables, except when used to accurately describe ingredients or flavored contained in a product.
- Likeness to images, characters, or phrases that are popularly used to advertise to children;
- Imitation of candy packaging or labeling, or other packaging and labeling of cereals, sweets, chips, or other food products typically marketed to children;
- The terms “candy” or “candies” or variants in spelling such as “kandy” or “kandee”;
- Brand names or close imitation of brand names of candies, cereals, sweets, chips, or other food products typically marketed to children;
- Any other image or packaging that is easily confused with commercially available foods that do not contain kratom and are typically marketed to children;
- Anything else that the State Department of Public Health (DPH) determines in regulation to be attractive to children; and,
- Anything else that is attractive to children in light of all relevant facts and circumstances.
- Use of images that are attractive to children, including but not limited to images of any of the following, accept as part of required health warnings:
- “Kratom leaf” to mean the leaf of a kratom plant, also known as mitragyna speciosa, any form.
- “Kratom leaf extract” to mean the material obtained by extraction of kratom leaves by any means.
- “Kratom product” to mean a product consisting of kratom leaf, kratom leaf extract, or both.
- “Total kratom alkaloids” to mean the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-hydroxymitragynine in a kratom product.
- Requires packaging of a kratom product or a 7-OH product offered for retail sale to be child resistant for the life of the product. Specifies that both of the following packages are considered child resistant for the purposes of this bill:
- A package that has been certified as child resistant under the requirements of the Poison Prevention Packaging Act of 1970 (15 United States Code (USC) § 1471, et seq.) and any regulations promulgated pursuant to that act; or
- Plastic packaging that is at least four mils thick and heat sealed without an easy-open tab, dimple, corner, or flap, provided that the package maintains its child resistance throughout the life of the product.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product or 7-OH product to a person under 21 years of age.
- Requires an online retailer or marketplace of a kratom product or 7-OH product to implement an age-verification system to ensure compliance with 3) above.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product or 7-OH product that is attractive to children.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing a kratom product or 7-OH product with a level of 7-hydroxymitragynine that is greater than 2% of the total kratom alkaloids in the product.
EXISTING LAW:
- Enacts the Sherman Law, enforced by DPH, which provides broad authority for DPH to enforce food safety requirements, including that food is not adulterated, misbranded, or falsely advertised. Food labeling requirements generally adopt federal food labeling laws as the state requirement, including nutrition labeling and allergen labeling, but DPH is permitted, by regulation, to adopt additional food labeling regulations. [Health and Safety Code (HSC) § 109875, et seq.]
- Prohibits any person from engaging in the manufacturing, packing, or holding of any processed food unless the person has a valid registration as a food processing facility from the DPH under the Sherman Law. [HSC § 110460]
- Establishes penalties for violations of the Sherman Law, including a fine of up to $1,000, or up to $10,000 for repeated violations. [HSC § 111825]
- Prohibits any manufacturer, wholesaler, retailer, or other person from selling, transferring, or otherwise furnishing a dietary supplement containing either of the following to a person under 18 years of age:
- A dietary supplement containing an ephedrine group alkaloid; or
- A dietary supplement containing any of the following: androstanediol, androstanedione, androstenedione, norandrostenediol, norandrostenedione, dehydroepiandrosterone. [HSC § 110423.2]
- Establishes a regulatory structure in DPH, under the Sherman Law, for food, beverage and cosmetic products containing industrial hemp, and limits these products to containing no more than 0.3% concentration of tetrahydrocannabinol (THC). Prohibits industrial hemp from including cannabinoids produced through chemical synthesis. [HSC § 111920 et seq., § 111920 (f)]
- Enacts the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) to establish a comprehensive system to control and regulate the cultivation, distribution, transport, storage, manufacturing, processing, and sale of both medicinal cannabis and cannabis products, and adult-use cannabis and cannabis products for adults 21 years of age and over, regulated by the Department of Cannabis Control (DCC). [Business and Professions Code § 26000, et seq.]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. The author states that as a physician specializing in addiction treatment, she has grown increasingly concerned about the use of Kratom and especially its derivative 7-OH. The author states that we have reached a point where state and federal regulators can no longer ignore these products. The author states that until the federal government does its job, California must act to protect our residents and especially our children. The author concludes that this bill is a reasonable first step to age gate these products as we consider additional regulatory protections to put in place.
- BACKGROUND. Kratom (Mitragyna speciosa) is a tree in the coffee family, found in Thailand and neighboring countries. These leaves are crushed and then smoked, brewed with tea, or placed into gel capsules. Kratom has a long history of use in Southeast Asia, where it is commonly known as thang, kakuam, thom, ketum, and biak. Traditionally, in Southeast Asia, people have chewed its leaves or made them into a tea that is used to fight fatigue and improve work productivity. Kratom has also traditionally been used during religious ceremonies and to treat symptoms such as pain and diarrhea, sometimes as a substitute for opium. In this bill, kratom leaf refers to the leaf of a kratom plant. The alkaloid content refers to the sum of the various alkaloids that are present in the leaf material that contribute the effect of the plant, including mitragynine, paynantheine, speciogynine, speciociliatine, and 7-hydroxymitragynine.
- Effects of kratom usage. Kratom leaves contain two major psychoactive ingredients, mitragynine and 7-hydroxymitragynine, which interact with opioid receptors in the brain. People who use kratom have reported both stimulant-like effects (increased energy, alertness, rapid heart rate) and effects like those of opioids and sedatives (relaxation, pain relief, confusion). Per the United States Drug Enforcement Administration (DEA), consumption of kratom tree leaves produces a stimulant effect in low doses, and a sedative effect in high doses. Consumption of kratom in high doses can also lead to psychotic symptoms, and psychological and physiological dependence.
According to the National Institutes of Health Center for Complementary and Integrative Health (NCCIH), people may use kratom to try to overcome opioid addiction, kratom itself may have the potential to be addictive. People have reported using kratom to manage opioid withdrawal symptoms and cravings, and researchers are studying whether kratom is helpful for this purpose. However, kratom has not been shown to be safe and effective for this or any other medical use. Regular kratom users may experience withdrawal symptoms if they stop using it.
NCCIH notes that a variety of side effects of kratom have been reported. They include mild effects, such as nausea, constipation, dizziness, and drowsiness, and rare but serious effects such as seizures, high blood pressure, and liver problems. Fatal overdoses from kratom alone appear to be extremely rare. The use of kratom in combination with other drugs has been linked to deaths and severe adverse effects such as liver problems. More research is needed on drug interactions involving kratom.
NCCIH highlights that the long-term effects of kratom use are not well understood. Harmful contaminants such as heavy metals and disease-causing bacteria have been found in some kratom products.
According to the DEA, the abuse of kratom has increased markedly in recent years. Several cases of psychosis resulting from use of kratom have been reported, where individuals addicted to kratom exhibited psychotic symptoms, including hallucinations, delusion, and confusion.
- Research on kratom use. According to a 2019 study titled, “Current perspectives on the impact of Kratom use”, the national poison center reporting database documented 1,807 calls related to kratom exposure from 2011 to 2017. The Centers for Disease Control and Prevention analyzed data on unintentional and undetermined opioid overdose deaths from the State Unintentional Drug Overdose Reporting System. Kratom was detected on postmortem toxicology testing in 152 cases of 27,338 overdose deaths from data collected from 11 states from July 2016 to June 2017 and 27 states from July 2017 to December 2017. Kratom was identified as the cause of death by a medical examiner in 91 of the 152 kratom-positive deaths, but was the only identified substance in just seven of these cases. Presence of additional substances in these seven kratom-only cases cannot be ruled out. The co-occurring substances in the 91 cases where kratom was identified as the cause of death include fentanyl (including analogs), heroin, benzodiazepines, prescription opioids, cocaine, and alcohol. Multi-substance exposures involving kratom, predominantly in combination with opioids, are associated with a greater odds ratio of admittance to a health care facility and occurrence of a serious medical outcome when compared to kratom-only exposure.
These data highlight that kratom use is associated with a complex population of poly-drug users and especially with opioid use disorder. The data further suggests that a deeper investigation into the toxicity of kratom is needed, especially focusing on drug–herb interactions.
- Legal Status of Kratom.
- National level. Kratom is currently legal and accessible online and in stores in many areas of the United States. In 2016, DEA published notice of its intent to place mitragynine and 7-hydroxymitragynine in Schedule I on an emergency basis, which would have criminalized possession of kratom and made distribution a felony. However, after receiving numerous comments from some Members of Congress, advocacy groups, and others, DEA withdrew that notice. DEA has listed kratom as a Drug and Chemical of Concern, but to date has not exercised its authority to schedule kratom or its active compounds under the federal Controlled Substances Act. Even though the DEA has listed kratom as a “drug of concern,” kratom and kratom compounds are not listed in the U.S. schedule of controlled substances. The federal Food and Drug Administration (FDA) has not approved kratom as safe and effective for any medical purpose. Under the Federal Food, Drug, and Cosmetic Act (FD+C Act), kratom is considered a new dietary ingredient since it was not marketed as a dietary ingredient in the United States before October 15, 1994; evidence of safety is required for new dietary ingredients.
- Legal Status of Kratom.
According to the FDA’s webpage, “FDA and Kratom,” the FDA has not approved any prescription or over-the-counter drug products containing kratom or its two main chemical components, mitragynine and 7-OH-mitragynine. If a new drug application is submitted for kratom (or one of its components) to treat a specific medical condition, FDA will review the scientific data to determine if a drug product containing kratom (or its components) is safe and effective to treat that specific medical condition. Consistent with FDA’s practice with unapproved substances, until the agency scientists can evaluate the safety and effectiveness of kratom (or its components) in the treatment of any medical conditions, FDA will continue to warn the public against the use of kratom for medical treatment. The agency will also continue to monitor emerging data trends to better understand the substance and its components. Kratom is not appropriate for use as a dietary supplement. FDA has concluded from available information, including scientific data, that kratom is a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury and, therefore, dietary supplements that are or contain kratom are adulterated under the federal FD+C Act. Further, FDA has determined that kratom, when added to food, is an unsafe food additive under federal law; food containing an unsafe food additive, such as kratom, is adulterated under federal law. Based on these determinations by FDA, kratom is not lawfully marketed as a dietary supplement and cannot be lawfully added to conventional foods. Therefore, kratom is not lawfully marketed in the U.S. as a drug product, a dietary supplement, or a food additive in conventional food.
FDA has issued a series of import alerts, most recently in July 2023, authorizing FDA personnel to seize imported kratom products from specified firms without physical inspection. FDA has also seized kratom products manufactured in the United States, including an April 2023 seizure of kratom products worth approximately $3 million from an Oklahoma company.
In October 2023, Members introduced essentially identical bills in both the House and the Senate to “protect access to kratom.” According to the Congressional Research Service, these bills would direct the Secretary of Health and Human Services to gather information about kratom and would limit the authority to impose regulations on kratom, including prohibiting requirements on kratom that are more restrictive than those for foods, dietary supplements, or dietary ingredients under the FD+C Act. Each bill would contain a non-preemption clause, which would permit states to either ban or regulate kratom. These bills have not progressed out of committee.
- Other States.
- Kratom bans: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin currently ban mitragynine and hydroxymitragynine or 7-hydroxymitragynine (kratom’s active alkaloids). Legislators in Indiana, Rhode Island, Wisconsin, and Vermont have introduced bills to replace existing bans with regulations that would permit the sale of kratom products.
- Age restriction: Arizona, Georgia, Illinois, Minnesota, Nevada, Oklahoma, Texas, and Utah ban sales to persons under 18 years of age.
- Strength: Arizona, Oklahoma, Texas, and Utah prohibit sale of products in which 7-hydroxymitragynine is greater than 2% of the total alkaloid content.
- Marketing to children: Utah prohibits flavoring or packaging that appeals to children and requires child-safe packaging. West Virginia’s recently adopted law requires the commissioner of agriculture to develop similar standards.
- Other States.
- Kratom in California. Some estimates show that nearly 25% of all kratom sales in the United States are in California. In March 2024, the city of Newport Beach approved an ordinance to prohibit the sale and distribution of kratom. The City of San Diego and Oceanside banned the use and sale of kratom in 2016. It has been reported that some manufacturers have created stronger and more potent kratom concentrates to put into their products. According to a 2023 study titled, “Kratom availability in California vape shops,” kratom was available in two-thirds of vape-and-smoke shops throughout California.
- Attractiveness to children. The Kratom Consumer Advisory Council (KCAC) put out a position statement in October 2024 highlighting their concerns regarding the marketing of kratom products that may appeal to children intentionally or unintentionally. KCAC noted that some products are sold in forms resembling popular candies, such as gummies, lollipops, chocolate bars, and cookies. These products often feature bright colors, mascots, and flavors that could attract young children or be mistaken for regular candy. KCAC noted that the ease of access to these products and their resemblance to well-known candy items raise concerns about accidental ingestion by younger children. This bill prohibits kratom products sold or distributed from being attractive to children.
- What is 7-OH? According to a 2019 study titled, “7-Hydroxymitragynine is an Active Metabolite of Mitragynine and a Key Mediator of its Analgesic Effects,” mitragynine is the major active alkaloid found in kratom, and that it is converted to the much more potent mu-opioid receptor agonist 7-OH in the liver. The study found that brain concentrations of 7-OH are sufficient to explain most or all of the opioid-receptor-mediated analgesic activity of mitragynine. At the same time, mitragynine was found in the brains of mice at very high concentrations relative to its opioid receptor binding affinity, suggesting that it does not directly activate opioid receptors. The results suggest a metabolism-dependent mechanism for the analgesic effects of mitragynine. This bill prohibits the sale of a kratom product or 7-OH product with a level of 7-hydroxymitragynine that is greater than 2% of the total kratom alkaloids in the product.
- SUPPORT. The California Narcotic Officers’ Association (CNOA) supports this bill and writes, synthesized 7-hydroxymitragynine (7-OH) products, referred to as “legal morphine,” are developed from kratom and have become 30 times more potent than morphine. CNOA continues that 7-OH produces opioid-like effects and can cause fatal overdoses, making their abuse a serious public health and safety concern. CNOA continues other adverse effects of 7-OH include psychotic symptoms, and psychological and physiological dependence. CNOA notes that natural kratom products generally contain no more than 66% of mitragynine as the main alkaloid and 2% of 7-hydroxymitragynine in the alkaloid fraction of the extract. CNOA continues that a number of states including Arizona, Oklahoma, Texas, and Utah have enacted bans on synthetic 7-OH exceeding 2% of total alkaloid content in products. CNOA notes that in California, natural kratom products remain unregulated and unrestricted. CNOA states that any one of any age can purchase kratom and synthesized 7-OH products. CNOA states that this addresses safety concerns about natural kratom and 7-OH products by implementing some common-sense measures to protect the public and our youth by establishing a: minimum age of 21 to purchase; requirement for child-resistant packaging; ban on marketing that appeals to children; limit on 7-OH content not to exceed 2% of the product’s total alkaloid content. CNOA concludes that AB 1088 will protect better consumers and our youth from dangerous products that have resulted in addiction and death in our state and across the country.
- OPPOSE. The Holistic Alternative Recovery Trust (HART) opposes this bill on the grounds that a cap of 2% of the total alkaloids allowed in a kratom leaf is so de minimis as to be meaningless when manufacturing a 7-OH product. HART directs readers to their April 1, 2025 letter where they expanded on their concerns. Highlights from the previous letter: HART’s belief that exploring the potential applications of 7-OH could contribute to discussions on addressing opioid misuse and strategies; evolving research on 7-OH; and concerns that the percentage cap is a fatally-flawed measure noting that bad actor manufacturers who wish to create a high mg 7-OH product can easily adhere to the percentage cap and add the corresponding amount of mitragynine, thereby releasing a dangerous but compliant product. HART concludes by stating that it hopes that a realistic approach to regulating 7-OH that is focused on the potential benefits to California consumers.
- RELATED LEGISLATION. AB 8 (Aguiar-Curry) would require an out-of-state hemp manufacturer who produces an industrial hemp product that is a food or beverage for sale in this state to register with the department. States that MAUCRSA does not prohibit a licensee from manufacturing, distributing, or selling products that contain industrial hemp or cannabinoids, extracts, or derivatives from industrial hemp, if the product complies with all applicable state laws and regulations.
- PREVIOUS LEGISLATION.
- AB 2365 (Haney) of 2024 would have established the Kratom Consumer Protection Program to provide a regulatory structure for kratom products, as provided. AB 2365 was held on the Senate Appropriations Committee suspense file.
- AB 45 (Aguiar-Curry), Chapter 576, Statutes of 2021 establishes a regulatory structure in DPH for food, beverage and cosmetic products containing industrial hemp, and limited these products to containing no more than 0.3% concentration of THC.
- SB 94 (Committee on Budget and Fiscal Review), Chapter 27, Statutes of 2017 establishes a single system of administration for cannabis laws in California, combining the Medicinal Cannabis Regulation and Safety Act with the Adult Use of Marijuana Act to create the Medicinal and Adult-Use Cannabis Regulation and Safety Act.
- POLICY COMMENTS. The author may wish to consider working with DPH to determine the appropriate regulatory structure for kratom at DPH, and continue to work with stakeholders to identify a cap for 7-OH in kratom and 7-OH products and whether milligrams would be an effective form of measurement.
- DOUBLE REFERRAL. This bill is double-referred, upon passage of this committee, it will be referred to the Assembly Committee on Environmental Safety and Toxic Materials.
REGISTERED SUPPORT / OPPOSITION:
Support
Arcadia Police Officers' Association
Brea Police Association
Burbank Police Officers' Association
California Association of School Police Chiefs
California Coalition of School Safety Professionals
California District Attorneys Association
California Narcotic Officers' Association
California Reserve Peace Officers Association
Claremont Police Officers Association
Cleanearth4kids.org
Corona Police Officers Association
Culver City Police Officers' Association
Fullerton Police Officers' Association
Los Angeles School Police Management Association
Los Angeles School Police Officers Association
Murrieta Police Officers' Association
Newport Beach Police Association
Palos Verdes Police Officers Association
Placer County Deputy Sheriffs' Assocation
Pomona Police Officers' Association
Riverside Police Officers Association
Riverside Sheriffs' Association
Santa Ana Police Officers Association
Oppose
Holistic Alternative Recovery Trust
7 individuals
Analysis Prepared by: Eliza Brooks / HEALTH / (916) 319-2097
Discussed in Hearing
Assembly Floor
Assembly Standing Committee on Environmental Safety and Toxic Materials
Assembly Standing Committee on Health
Bill Author
Bill Co-Author(s):